

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/12, 15/54, 15/55, C07K 14/47, C12N 9/12, 9/10, C07K 1/113, 7/06, 7/08, C12Q 1/42, 1/48, G01N 33/68	A2	(11) International Publication Number: WO 96/16172 (43) International Publication Date: 30 May 1996 (30.05.96)
(21) International Application Number: PCT/US95/16039 (22) International Filing Date: 22 November 1995 (22.11.95) (30) Priority Data: 08/344,227 23 November 1994 (23.11.94) US 08/404,731 15 March 1995 (15.03.95) US 08/503,226 17 July 1995 (17.07.95) US (71) Applicants: ICOS CORPORATION [US/US]; 22021 20th Avenue, S.E., Bothell, WA 98021 (US). THE STATE OF OREGON, acting by and through THE OREGON STATE BOARD OF HIGHER EDUCATION, and on behalf of OREGON HEALTH SCIENCES UNIVERSITY [US/US]; 3181 S.W. Sam Jackson Park Road, Portland, OR 97201-3098 (US). (72) Inventors: LOCKERBIE, Robert, Owen; 11111 109th Place, N.E., Kirkland, WA 98033 (US). COGHLAN, Vincent, M.; 2930 S.W. Periander, Portland, OR 97201 (US). HOWARD, Monique, L.; 4723 48th Avenue S.E., Seattle, WA 98118 (US). GALLATIN, William, M.; 8412 S.E. 33rd Place, Mercer Island, WA 98040 (US). SCOTT, John, D.; 6630 S.W. Gable Parkway, Portland, OR 97255 (US).		(74) Agent: WILLIAMS, Joseph, A., Jr.; Marshall, O'Toole, Gerstein, Murray & Borun, 6300 Sears Tower, 233 South Wacker Drive, Chicago, IL 60606-6402 (US). (81) Designated States: AU, BR, CA, CN, CZ, FI, HU, JP, MX, NO, PL, RU, SK, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>Without international search report and to be republished upon receipt of that report.</i>
(54) Title: MODULATORS OF ANCHORING PROTEIN FUNCTION (57) Abstract The present invention provides compositions and methods useful for isolating calcineurin as well as inhibiting calcineurin activity. The compositions are peptides that contain regions that are homologous to calcineurin-binding regions of AKAP 79. Also provided are methods for determining if a cell contains a calcineurin-binding and PKA-binding anchoring protein that are useful for identifying additional proteins that bind both calcineurin and PKA. Another aspect of the present invention is methods for enhancing expression of interleukin 2 by T cells.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

- 1 -

MODULATORS OF ANCHORING PROTEIN FUNCTION

This application is a continuation-in-part of co-pending U.S. Patent Application Serial No. 08/503,226, filed July 17, 1995, which, in turn, 08/404,731, filed March 15, 1995, which, in turn, is a continuation-in-part of
5 co-pending U.S. Patent Application No. 08/344,227, filed November 23, 1994.

FIELD OF THE INVENTION

The present invention relates generally to regulation of the phosphatase enzymatic activity of calcineurin and modulation of interleukin 2
10 expression by T cells. More particularly, the present invention relates to inhibition of calcineurin's phosphatase activity by certain peptides and enhancement of T cell expression of interleukin 2 by treatment of the cells with certain other peptides.

BACKGROUND OF THE INVENTION

15 Calcineurin is a Ca^{2+} /calmodulin-dependent protein phosphatase and is a participant in many intracellular signaling pathways. Guerini and Klee, *Proc. Natl. Acad. Sci. USA* 86:9183-9187 (1989). The enzyme has been identified in eukaryotic cells ranging from yeast to mammals. Cyert and Thorner, *J. Cell. Biol.*, 107:841a (1989) and Klee et
20 al., *Adv. Enzymol.*, 61:149-200 (1984). Because calcineurin may participate in many signaling pathways in the same cell, some means of specific targeting of calcineurin's activity must exist. One cellular means for specifically targeting enzyme activity is by compartmentalization. Compartmentalization segregates signaling pathways and contributes to the specificity of cellular
25 responses to different stimuli. Compartmentalization of certain enzymes occurs by interaction of the enzymes with specific anchoring proteins. For example, cAMP-dependent protein kinase (PKA) is anchored at specific intracellular sites by binding to A-Kinase Anchor Proteins (AKAPs). Because

- 2 -

AKAPs have been demonstrated to bind proteins other than PKA, the family of proteins is generally referred to herein as anchoring proteins. Hirsch et al., *J. Biol. Chem.*, 267:2131-2134 (1992). cAMP activates PKA by binding to the regulatory subunits (R) of the dormant PKA holoenzyme and causes the release of the active catalytic subunit (C). Two classes of R subunit exist; RI and RII which form the type I and type II PKA holoenzymes, respectively. The subcellular distributions of these PKA isoforms appear to be distinct. The RI isoforms (RI α and RI β) are reported to be predominantly cytoplasmic and are excluded from the nuclear compartment, whereas up to 75% of the RII isoforms (RII α or RII β) are particulate and associated with either the plasma membrane, cytoskeletal components, secretory granules, the golgi apparatus, centrosomes or possibly nuclei.

Anchoring proteins have been identified in a variety of organisms. At least seven proteins that bind the regulatory subunit of PKA in *Aplysia californica*, a marine invertebrate have been identified. Cheley et al., *J. Biol. Chem.*, 269:2911-2920 (1994). One of these proteins is enriched in crude membrane fractions and taxol-stabilized microtubules and may thus anchor microtubules to the cell membrane as well as bind PKA. A mammalian anchoring protein has been identified that is related to microtubules; microtubule-associated protein 2 (MAP2) attaches PKA to the cytoskeleton. Threurkauf and Vallee, *J. Biol. Chem.*, 257:3284-3290 (1982) and DeCamilli et al., *J. Cell Biol.*, 103:189-203 (1986). The PKA-binding site on MAP2 is a 31-residue peptide in the amino-terminal region of the molecule. Rubino et al., *Neuron*, 3:631-638 (1989) and Obar et al., *Neuron*, 3:639-645 (1989).

Another anchoring protein that associates with microtubules, AKAP 150, accumulates in dendrites in close association with microtubules. Glantz et al., *Mol. Biol. Cell*, 3:1215-1228 (1992). AKAP 150 is present in several neuronal cell types and is a member of a family of anchoring proteins that are the principal anchoring proteins in mammalian brain. Other members

- 3 -

of this family include AKAP 75 found in bovine brain and AKAP 79 found in human brain. Glantz et al., *J. Biol. Chem.*, 268:12796-12804 (1993). AKAP 75 apparently binds cytoskeletal elements through two non-contiguous regions near the N-terminus of AKAP 75. AKAP 79 is predominantly present in postsynaptic densities (PSDs) in the human forebrain. Carr et al., *J. Biol. Chem.*, 267:16816-16823 (1992).

Other anchoring proteins have also been characterized. Exposure of granulosa cells to follicle-stimulating hormone and estradiol has been demonstrated to up-regulate expression of an 80 kDa AKAP. Carr et al., *J. Biol. Chem.*, 268:20729-20732 (1993). Another AKAP, Ht31, has been cloned from a human thyroid cDNA library. Carr et al., *J. Biol. Chem.*, 267:13376-13382 (1992). Another anchoring protein, AKAP 95, changes its intracellular location during the cell cycle. AKAP 95 is an integral nuclear protein during interphase, but becomes associated with cytoplasmic PKA when the nuclear membrane breaks down during mitosis. This suggests that AKAP 95 could play a role in targeting activity of certain isoforms of PKA during cAMP-responsive events linked to the cell cycle. Coghlan et al., *J. Biol. Chem.*, 269:7658-7665 (1994). Other known anchoring proteins include an 85 kDa AKAP which links PKA to the Golgi apparatus (Rios et al., *EMBO J.*, 11:1723-1731 (1992)) and a 350 kDa AKAP that binds PKA to centromeres (Keryer et al., *Exp. Cell Res.*, 204:230-240 (1993)).

The known anchoring proteins bind PKA by a common mechanism. Although the primary structure of the anchoring proteins is not conserved, each has a secondary structure motif that includes an amphipathic helix region. Scott and McCartney, *Mol. Endo.*, 8:5-11 (1994). Binding of anchoring proteins to the regulatory subunit of PKA is blocked by a peptide that mimics this helical structure of the PKA binding region of anchoring proteins. Disruption of the peptide's helical structure by an amino acid substitution abolishes the PKA-anchoring protein binding block (Carr et al., *J. Biol. Chem.*, 266:14188-14192 (1991)), demonstrating that PKA binding

- 4 -

occurs in the amphipathic helix of anchoring proteins and is governed by the secondary structure of the anchoring protein molecules. This intracellular binding and localization of PKA by anchoring proteins provides a means for segregation of a kinase that, like calcineurin, is common to many signaling pathways yet may act in a pathway-specific manner.

PKA functions in many intracellular pathways. For example, inhibition of binding between AKAP 79 and PKA in hippocampal neurons has been shown to inhibit alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid/kainate glutamate receptors. Rosenmund et al., *Nature*, 368:853-856 (1994). This indicates that PKA regulates these receptors. PKA also regulates the activity of glycogen phosphorylase by reversibly phosphorylating the enzyme in response to hormonally-induced increases in intracellular cAMP. Walsh et al., *J. Biol. Chem.*, 243:3763-3765 (1969). cAMP has also been shown to inhibit signaling through MAP Kinase pathways. Wu et al., *Science*, 262:1065-1072 (1993). This inhibition is mediated by activation of PKA that inhibits Raf-1 activation by Ras, thereby blocking the MAP Kinase pathway. Vojtek et al., *Cell*, 74:205-214 (1993) and Hafner et al., *Mol. Cell Biol.*, 14:6696-6703 (1994). These pathways are important in many cell types and have been implicated in many cell functions, such as the transcriptional activation of the interleukin 2 gene that is important in activation of T cells. Weiss and Littman, *Cell*, 76:263-274 (1994); Owaki et al., *EMBO J.*, 12:4367-4373 (1993).

Like PKA, calcineurin is associated with T cell activation. Clipstone and Crabtree, *Nature*, 357:695-697 (1992); O'Keefe et al., *Nature*, 357:692-694 (1992). In T cells, calcineurin participates in regulation of IL-2 expression following T cell stimulation. Weiss and Littman, *supra*. Nuclear factor of activated T cells (NFAT_p) has been shown to be a substrate for calcineurin phosphatase activity. It has been suggested that, following T cell stimulation, calcineurin-mediated NFAT_p dephosphorylation allows translocation of NFAT_p from the cytoplasm to the nucleus where NFAT_p

- 5 -

interacts with Fos and Jun to induce expression of the IL-2 gene. Jain et al., *Nature*, 365:352-355 (1993).

Calcineurin's role in T cell activation provides a target for therapeutic intervention into T cell-mediated disorders and various medications
5 have been developed that inhibit calcineurin. Two calcineurin-inhibiting drugs, cyclosporin A (cyclosporin) and FK506, have been used in the clinic. Thomson and Starzl, *Immunol. Rev.*, 136:71-98 (1993). Both cyclosporin and FK506 inhibit calcineurin only after binding to distinct intracellular proteins known as immunophilins (cyclophilin and FKBP 12, respectively). Schreiber
10 and Crabtree, *Immunology Today*, 13:136-142 (1992). Thus, cyclosporin and FK506 act as prodrugs. Following binding to their respective immunophilins, the drug/immunophilin complexes bind calcineurin, thereby inhibiting the phosphatase activity.

Calcineurin inhibition has been most effectively exploited in the
15 treatment of graft rejection following organ transplantation. Cyclosporin and FK506 have been employed following renal, hepatic, cardiac, lung, and bone marrow transplants. The Canadian Multicentre Transplant Study Group, *N. Engl. J. Med.*, 314:1219-1225 (1986); Oyer et al., *Transplant Proc.*, 15:Suppl 1:2546-2552 (1983); Starzl et al., *N. Engl. J. Med.*, 305:266-269 (1981); The
20 Toronto Lung Transplant Group, *JAMA*, 259:2258-2262 (1988); and Deeg et al., *Blood*, 65:1325-1334 (1985). The use of these medications has significantly prolonged graft survival and lessened morbidity following transplant. Najarian et al., *Ann. Surg.*, 201:142-157 (1985) and Showstack et al., *N. Engl. J. Med.*, 321:1086-1092 (1989).

25 Cyclosporin also has been used in a variety of autoimmune-related diseases. Uveitis generally improves within a few weeks of therapy, but quickly relapses after cyclosporin is discontinued. Nussenblatt et al., *Am J. Ophthalmol.*, 96:275-282 (1983). Similarly, psoriasis generally improves with cyclosporin therapy, but quickly relapses after treatment. Ellis et al.,
30 *JAMA*, 256:3110-3116 (1986). "Honeymoon" periods of insulin independence

- 6 -

may be induced and prolonged in both new onset Type I and Type II diabetes mellitus when cyclosporin is administered within two months of insulin therapy. Feutren et al., *Lancet*, 2:119-124 (1986) and Bougneres et al., *N. Engl. J. Med.*, 318:663-670 (1988). A variety of nephropathies, including
5 minimal-change focal and segmental, membranous, and IgA-mediated nephropathies, may also be sensitive to cyclosporin, although observed reductions in proteinuria may be due to a decrease in the glomerular filtration rate and not healing of the basement membrane. Tejani et al., *Kidney Intl.*, 29:206 (1986). Cyclosporin administration also has a dose-dependent effect
10 on rheumatoid arthritis, although such treatment is associated with a high incidence of nephrotoxicity. Førre et al., *Arthritis Rheum.*, 30:88-92 (1987).

As mentioned above, cyclosporin has been associated with nephrotoxicity. Mason, *Pharmacol. Rev.*, 42:423-434 (1989). Depressed renal function occurs in virtually all patients treated with cyclosporin. Kahan,
15 *N. Engl. J. Med.*, 321:1725-1738 (1989). This can generally be reversed by cessation of cyclosporin therapy. Unfortunately, in organ graft recipients substitution of other commonly used immunosuppressives for cyclosporin carries a high risk of graft rejection. In renal transplant patients this can require reinstitution of dialysis. In patients that have received hearts, lungs,
20 or livers, graft rejection can be fatal. Although less common than nephrotoxicity, neurotoxicity and hepatotoxicity are also associated with cyclosporin therapy. de Groen et al., *N. Engl. J. Med.*, 317:861-866 (1987) and Kahan et al., *Transplantation*, 43:197-204 (1987).

Significant toxicity has also become apparent in the use of
25 FK506. Like cyclosporin, FK506 is associated with nephrotoxicity. Peters et al., *Drugs*, 4:746-794 (1993). The clinical presentation, lesion morphology, and incidence are approximately equivalent to those of cyclosporin. McCauley, *Curr. Op. Nephrol. Hyperten.*, 2:662-669 (1993). Neurotoxicity has also been associated with FK506. Eid Iman et al.,
30 *Transplant. Proc.*, 23:3175-3178 (1991) and Fung et al., *Transplant. Proc.*,

- 7 -

23:3105-3108 (1991). In contrast to cyclosporin, FK506 has a hepatotrophic, rather than hepatotoxic, effect. Peters et al., *supra*.

In view of the significant potential toxicity of immunosuppressive agents, such as cyclosporin and FK506, it is clear that there is a need in the art for additional agents that inhibit calcineurin. These agents would preferably be associated with fewer toxic side effects than presently available agents and thus could provide an advance in immunosuppressive therapy. Additionally, there is a need for agents that inhibit PKA in T cells allowing enhanced expression of interleukin 2 by the cells.

SUMMARY OF THE INVENTION

The present invention is based, in part, on the discovery that calcineurin binds AKAP 79. By binding both PKA and calcineurin, AKAP 79 co-localizes a kinase and a phosphatase that may regulate flux through a specific signaling pathway. The present invention accordingly provides compositions and methods for isolating calcineurin as well as for inhibiting calcineurin activity in a cell. The isolation methods comprise contacting a cellular fraction with AKAP 79 or a calcineurin-binding fragment thereof which has been immobilized to a solid substrate and then eluting calcineurin therefrom. The calcineurin inhibiting methods comprise contacting the cell with AKAP 79 or a calcineurin-binding fragment peptide thereof. Preferably, the calcineurin-binding peptide does not also bind PKA. Preferred peptides comprise the following amino acid sequence:

Arg-Arg-Lys-Arg-Ser-Gln-Ser-Ser-Lys-Glu-Glu-Lys-Pro

(SEQ ID NO:1).

Alternative peptides useful in the practice of the calcineurin inhibiting methods of the present invention include:

Arg-Arg-Lys-Arg-Ser-Gln-Ser-Ser-Lys-Glu-Glu-Lys-Pro-Leu-Gln

(SEQ ID NO:2)

- 8 -

and

Arg-Arg-Lys-Arg-Ser-Gln-Ser-Ser-Lys-Glu-Glu-Lys-Pro-Phe-Lys
(SEQ ID NO:3).

5 These peptides are homologous to amino acid sequences of AKAP 79 that bind calcineurin. Although the peptides are similar to the calcineurin binding region of FKBP12, unlike calcineurin inhibition by the FK506/FKBP12 complex, the peptides inhibit calcineurin activity without requiring interaction with another molecule.

10 The peptides may be modified to facilitate passage into the cell, such as by conjugation to a lipid soluble moiety. For example, the peptides may be conjugated to myristic acid. Alternatively, the peptides may be packaged in liposomes that may fuse with cell membranes and release the peptides into the cells.

15 Another aspect of the present invention are methods for determining if a cell contains a calcineurin-binding and PKA-binding anchoring protein. The methods generally comprise lysing the cell to form a lysate; incubating the lysate with a solid support, which solid support has calcineurin molecules immobilized thereon; washing the lysate from the solid support; contacting the solid support with a labeled PKA regulatory subunit, washing unbound regulatory subunit from the solid support; detecting label
20 remaining on the solid support; and determining therefrom the presence of a calcineurin-binding and PKA-binding anchoring protein in the cell. Alternatively, the PKA regulatory subunit may be immobilized on the solid support and calcineurin may be the labeled molecule. Generally, the PKA regulatory subunit will be an RII subunit.
25

These methods are useful for identifying additional proteins that bind both PKA and calcineurin. Identification of other such proteins may provide tissue specific targets for therapeutic intervention.

30 Also comprehended by the present invention are methods for identifying compounds that modulate binding between calcineurin and a

- 9 -

calcineurin anchoring protein. Either calcineurin or the anchoring protein may be bound to a solid substrate. The unbound binding partner is detectably labeled. The binding partners are incubated in the presence of a test compound. The effect of the test compound on binding between calcineurin and the calcineurin anchoring protein is determined by observing the amount of label bound to the immobilized binding partner. A reduction in the amount of label bound in the presence of the test compound compared to the amount of label bound in the absence of the test compound indicates that the test compound is an inhibitor of binding between calcineurin and the calcineurin anchoring protein. Other assays, such as scintillation proximity assays may also be employed.

An additional aspect of the present invention includes methods for enhancing expression of interleukin 2 by T cells. Inhibition of the kinase activity of PKA or localization of PKA in T cells enhances the expression of proteins under the control of the promoter elements that regulate transcription of the interleukin 2 gene. These methods generally comprise contacting the T lymphocyte with one of the following amino acid sequences:

Gly-Arg-Arg-Asn-Ala-Ile-His-Asp-Ile

(SEQ ID NO:5), or

Asp-Leu-Ile-Glu-Glu-Ala-Ala-Ser-Arg-Ile-Val-Asp-Ala-Val-Ile-Glu-

Gln-Val-Lys-Ala-Ala-Gly-Ala-Tyr

(SEQ ID NO:9).

The peptide of SEQ ID NO:5 is a peptide that inhibits the kinase activity of PKA. The peptide of SEQ ID NO:9 is a peptide that is homologous to a PKA binding region of the HT31 anchoring protein. These peptides may be modified to facilitate passage into cells or packaged into liposomes as described above. The invention contemplates a variety of uses for the methods employing the peptides. For example, the methods may be employed to stimulate the immune response, to stimulate activated T cells for selected clonal expansion, or to enhance T cell responses to experimental stimuli for

- 10 -

evaluation of early events in T cell biology and activation of the immune response.

BRIEF DESCRIPTION OF THE FIGURES

5 Figs. 1A-1B illustrate inhibition of calcineurin phosphatase activity by full-length AKAP 79 and a calcineurin-binding fragment of AKAP 79.

Figs. 2A-2C illustrate subcellular localization of type II PKA and calcineurin as well as the co-localization of type II PKA and calcineurin.

10 Fig. 3 illustrates homology between clone 11.1 and human calcineurin isoform 11.1.

Fig. 4 illustrates the increase in intracellular cAMP concentration induced by treatment of Jurkat cells with forskolin and IBMX.

15 Figs. 5A-5H illustrate FACS plots that demonstrate the effect of PKA inhibition and delocalization on transcription of proteins controlled by the interleukin 2 promoter.

DETAILED DESCRIPTION OF THE INVENTION

The peptides employed in the methods of the present invention may be synthesized in solution or on a solid support in accordance with conventional techniques as described in Stewart and Young, *Solid Phase*
20 *Peptide Synthesis*, 2nd ed., Pierce Chemical Company, (1984) or Tam et al., *J. Am. Chem. Soc.*, 105:6442 (1983), both of which are incorporated herein by reference. The peptides may be myristoylated by standard techniques as described in Eichholtz et al., *J. Biol. Chem.*, 268:1982-1986 (1993), incorporated herein by reference. Encapsulation of the peptides in liposomes
25 may also be performed by standard techniques as generally described in U.S. Patent Nos. 4,766,046; 5,169,637; 5,180,713; 5,185,154; 5,204,112; and 5,252,263 and PCT Patent Application No. 92/02244, each of which is incorporated herein by reference.

- 11 -

The following examples are offered by way of illustration and not of limitation. Example 1 describes association of calcineurin with AKAP 79 and PKA. Example 2 relates to inhibition of calcineurin activity using peptides derived from AKAP 79 amino acid sequences. Example 3 addresses subcellular distribution of type II PKA and calcineurin. Example 4 describes a di-hybrid assay that demonstrates physiological binding between AKAP 79 and calcineurin. Example 5 addresses analysis of AKAP 79 and calcineurin binding. Example 6 describes use of calcineurin mutants to define an AKAP 79 binding site. Example 7 relates to interaction between AKAP 79 and PKA RI subunit. Example 8 describes a method to screen for inhibitors of PKA compartmentalization. Example 9 describes anchoring protein participation in modulation of IL-2 expression. Example 10 relates to identification of other AKAP 79 binding proteins. Example 11 describes interaction between AKAP 79 and PKC. Example 12 relates to potential therapeutic application of anchoring proteins.

Example 1

This example demonstrates the naturally-occurring association of calcineurin with AKAP 79 and PKA. AKAP 79 thus functions to co-localize both a ubiquitous kinase and ubiquitous phosphatase. This co-localization may provide for specific regulation of enzymes in signaling pathways through phosphorylation or dephosphorylation of the enzymes.

Immunoprecipitation of calcineurin (CaN) from a calmodulin-agarose purified bovine brain extract was achieved using affinity-purified antibodies specific for either CaN A or CaN B as generally described in Harlowe and Lane, *Antibodies: A Laboratory Manual*, Cold Spring Harbor Press, Cold Spring Harbor, NY (1988), except a final wash using buffer A (10 mM HEPES pH 7.9, 1.5 mM MgCl, 10 mM KCl, 1 mM PMSF and 10 μ M IBMX) + 0.4 M NaCl was included. PKA activity was measured as described in Scott et al., *Proc. Natl. Acad. Sci. USA*, 82:4379-4383 (1985),

- 12 -

incorporated herein by reference, after elution of the immunoprecipitate with 0.1 mM cAMP. Phosphorylation of immunoprecipitated proteins was initiated by addition of 0.1 mM ^{32}P -ATP (1.5×10^5 cpm/nmol) and, after 30 min at 30°C, reactions were terminated by addition of SDS-loading buffer and subjected to SDS-PAGE. PKA R-subunit was purified from the 30-60% $(\text{NH}_4)_2\text{SO}_4$ fraction of brain extract using cAMP-agarose by the methods described in Coghlan et al., *J. Biol. Chem.*, 269:7658-7665 (1994) (incorporated herein by reference), except protein was eluted with 0.5 mM Ht31 peptide (SEQ ID NO:4). Western blots and PKA RII overlays were performed as described in Coghlan et al., *supra*.

Kinase activity was detected in the calmodulin purified extract, was enriched 123 ± 3.6 fold (\pm standard deviation; $n=3$) in the CaN immunoprecipitate, and was specifically inhibited by a peptide that inhibits PKA kinase activity, PKI peptide (SEQ ID NO:5), indicating that the catalytic (C) subunit of PKA was a component of the isolated complex. The bovine homologue of AKAP 79 (AKAP 75) and RII, both substrates for the C subunit, were also present in the immunoprecipitate and were phosphorylated upon addition of cAMP and ^{32}P -ATP. In complementary experiments, R subunits of PKA were isolated from crude extracts of bovine brain by affinity chromatography on cAMP-agarose. Treatment of the affinity column with Ht31 peptide specifically eluted AKAP 75 from the cAMP-bound RII and also released both CaN A and B subunits. Approximately 5% of the total CaN present in the lysate was found to be associated with AKAP 75 and RII as detected on western blots. Combined, these results suggest simultaneous association of PKA and CaN with the anchoring protein.

Example 2

This example demonstrates inhibition of the phosphatase activity of calcineurin by peptides from AKAP 79.

- 13 -

To determine whether AKAP 79 peptide binding was inhibitory, calcineurin (CaN) activity was assayed in the presence of recombinant AKAP 79. Briefly, recombinant AKAP 79 was expressed in *E. coli* as described in Carr et al., *J. Biol. Chem.*, 267:16816-16823 (1992), incorporated herein by reference. CaN and the constitutively active truncation mutant CaN₄₂₀ (a truncated, Ca²⁺/calmodulin independent constitutively active form of CaN (Perrino et al., *J. Biol. Chem.*, in press)) were expressed in Sf9 cells and purified on calmodulin-Sepharose as described in Perrino et al., *J. Biol. Chem.*, 267:15965-15969 (1992), incorporated herein by reference.

Phosphatase activity toward ³²P RII peptide substrate was measured as described in Perrino et al., *supra*. CaN (30 nM), calmodulin (100 nM) and ³²P RII peptide (22 μM) were incubated with AKAP 79 protein and AKAP 79 peptide (SEQ ID NO:1-amino acids 81-102) over the range of concentrations indicated in Fig. 1B. Calmodulin was omitted from CaN₄₂₀ assays. ³²P released from the substrate was measured in triplicate samples in three separate experiments by scintillation counting. The inhibition constant (K_i) of recombinant AKAP 79 for CaN was determined by linear regression analysis of data. K_i values for AKAP 79 peptide were estimated by determining the IC₅₀ using a fixed substrate concentration at K_m (42 μM).

Fig. 1A illustrates a Lineweaver-Burk plot of AKAP 79 inhibition of both full-length CaN (Ca²⁺/calmodulin dependent) (circles) and CaN₄₂₀ (squares) in a non-competitive manner with respect to phosphorylated RII peptide substrate. The open symbols represent phosphatase activity in the absence of AKAP 79 and the filled symbols represent phosphatase activity in the presence of AKAP 79. The synthetic peptide corresponding to the AKAP 79 peptide inhibited both full-length CaN (filled circles) and CaN₄₂₀, whereas the Ht31 peptide was not an inhibitor of CaN (Fig. 1B). The observed inhibition was specific for calcineurin; the AKAP 79 peptide did not significantly affect the activity of protein phosphatases 1 (open diamonds) or 2A (crosses) at peptide concentrations as high as 0.4 mM. Although CaN-

- 14 -

binding sites on AKAP 79 and FKBP-12 are similar, their differences may have functional significance: FK506 (2 μ M) did not affect the potency of inhibition and recombinant AKAP 79 did not display peptidyl prolyl isomerase activity toward a fluorescent peptide substrate. Further, the CaN B subunit
5 which is required for FK506/FKBP interaction with the CaN A subunit is not required for interaction of AKAP 79 with the CaN A subunit. Also, while the FK506/FKBP interaction with CaN A is calcium/calmodulin dependent, the AKAP 79 inhibition of calcineurin activity is calcium/calmodulin independent. Collectively, these findings suggest that CaN in its inactive state is localized
10 by AKAP 79 in a manner analogous to anchoring protein-bound PKA.

Example 3

This example demonstrates subcellular distribution of type II PKA and calcineurin in various tissue.

The subcellular location of many protein kinases and protein
15 phosphatases is defined by association with targeting subunits. AKAP 79 represents a novel member of this class of regulatory proteins as it serves a bifunctional role in localizing both PKA and CaN.

Cells were cultured, formalin-fixed, and immunostained as described in Rosenmund et al., *Nature*, 368:853-856 (1994). FITC-conjugated
20 anti-goat secondary antisera was used for RII staining. Biotinylated anti-rabbit secondary antisera and streptavidin-Texas-Red (Jackson) were used in staining for CaN. Images were obtained using a Biorad MRC-600 confocal laser scanning system (A1 and A2 filters) with a Nikon optiphot 2 microscope equipped with 60x planapcho chromat (1.6 NA) oil immersion lens. Confocal
25 sections were between 1.5 and 2 μ m absolute thickness.

AKAP 79 homologues were observed in bovine, porcine, rabbit, and murine brain. This indicates that co-localization of PKA and CaN may be a universal phenomenon that adapts neurons for specific signal transduction events. Using immunocytochemical methods, the subcellular

- 15 -

distribution of type II PKA and CaN was examined in cultured hippocampal neurons. The staining patterns for RII (green label in Fig. 2A) and CaN (red label in Fig. 2B) were regionally dispersed and overlapped in the neurites (RII is red and CaN is green in Fig. 2C). These findings are consistent with co-localization of type II PKA and CaN by the anchoring protein and suggest a role for the ternary complex in regulating synaptic transmission. This is consistent with experiments demonstrating co-localization of RII and AKAP 79 in these cells, and by studies showing that AKAP 79, type II PKA and CaN are components of postsynaptic densities. Potential substrates for the localized ternary transduction complex may include AMPA/kainate receptors, which are modulated by anchoring protein-targeted PKA.

Example 4

This example demonstrates interaction between AKAP 79 and calcineurin in a yeast dihybrid assay. Employing AKAP 79 as the "bait", calcineurin encoded by cDNA from a murine T cell library was found to bind to AKAP 79.

The assay was performed as generally described in Durfee, et al., *Genes and Development* 7:555-567 (1993), incorporated herein by reference. The "target" and "bait" were two plasmids, each containing part of the Gal-4 transcription factor. The "bait" plasmid (pAS1) was a 2 micron based plasmid with an ADH promoter linked to the Gal-4 DNA binding subunit [amino acids 1-147 as described in Keegan et al., *Science*, 231:699-704 (1986), incorporated herein by reference], followed by a hemagglutinin (HA) tag, polyclonal site and an ADH terminator. Selection was maintained using SC-Trp media. The "target" construct was a leu2, 2 micron based plasmid containing an ADH promoter and terminator with the Gal-4 transcription activation domain II [amino acids 768-881 as described in Ma and Ptashne, *Cell*, 48:847-853 (1987), incorporated herein by reference] followed by a multiple cloning site. This vector, pACT, was utilized in the

- 16 -

construction of a mouse T cell cDNA fusion library. *Saccharomyces cerevisiae* y190 used in the screening was designed with two reporter genes integrated into its genome. The reporter genes are under control of a Gal-1 promoter containing Gal-4 binding sites. If the proteins encoded by the bait
5 plasmid and the target plasmid associate, the Gal-4 transcription factor subunits are brought together and function to initiate transcription of the reporter genes.

A 1.3 Kb NcoI/BamHI fragment containing the coding region of AKAP 79 was isolated from a pET11d backbone and ligated to pAS1 to act
10 as "bait" for the screen. One μ g of this construct was transformed into y190 MAT α and y190 MAT α using a standard lithium acetate-PEG transformation protocol. Four isolates of each mating type (y190A pAS1 AKAP 79 1-4 and y190 α pAS1 AKAP 79 1-4) were tested for their ability to interact with a fusion construct pACT-RII which contains the regulatory subunit (RII amino
15 acids 1-89) of PKA. This was achieved by mating the strains on YEPD (1% Bacto-yeast extract, 2% Bacto-peptone, 2% dextrose, and 2% Bacto agar) overnight at 30°C and then selecting for diploids on SC-Leu-Trp plates. The *E. coli* lac Z gene acting as the reporter could then be assayed for β -galactosidase activity. The mated strains were replicated to SC-Leu-Trp plates
20 that had been overlaid with Hybond-N filters (Amersham) and grown overnight. The filters were placed in liquid nitrogen for one minute to crack open the yeast. A 3MM paper disc was saturated with approximately 3 ml 0.1% X-gal in 60 mM Na₂HPO₄, 40 mM NaH₂PO₄, 10 mM KCl and 10 mM MgSO₄. The lysed yeast filter was placed on top of the disc and allowed to
25 develop at 30°C for approximately 1-2 hours. Diploid strains containing both pAS1 AKAP 79 and pACT RII fusions that were positive for β -gal activity were indicated by turning the yeast patch a blue color. As a control, the bait AKAP 79 plasmid remained white when mated with an empty pACT control.

- 17 -

Detection of the Gal-4 AKAP 79 fusion protein was achieved by growing y190A AKAP 79 (isolates 1 and 2) and y190a AKAP 79 (isolates 1 and 2) to a density of 2×10^7 cells/ml in 50 ml SC-Trp media. Cells were pelleted at $3000 \times g$ for 10 minutes and lysed with 200 μ l glass beads (size 425-600 microns) in 25 mM Tris pH8, 5 mM EDTA, 5 mM EGTA, 2 mM O-phenanthroline, 1 mM DTT, 25 μ M 4-(2-aminoethyl)-benzenesulfonyl fluoride-HCl, molecular weight 239.5 (AEBSF), 1 mM benzanidine, 1 μ g/ml PLACC (pepstatin, leupeptin, aprotinin, calpain I and II), and 20 μ g/ml bestatin lysis buffer. Cells were alternately vortexed for one minute and iced for one minute for a total of 24 minutes (12 cycles). Protein concentrations were determined and 30 μ g of total protein was loaded onto 10% SDS-PAGE gel. The gel was wet transferred to Immobilon-P (Millipore) and detected by standard procedures using an anti-HA monoclonal antibody 12CA5 (Bab Co., Berkeley, CA) and goat anti-mouse IgG alkaline phosphatase conjugated secondary antiserum (Biorad, Hercules, CA). A Gal-4 AKAP 79 fusion protein of approximately 100 kDa was readily detectable indicating the correct size product was present within these strains.

The y190A pAS1 AKAP 79 isolate 1 was chosen to screen a pACT murine T cell cDNA library. A 500 ml SC-Trp culture ($OD_{600} = 0.6-0.8$) was harvested, washed with 100 ml distilled water, and repelleted. The pellet was brought up in 50 ml LiSORB (100 mM lithium acetate, 10 mM Tris pH8, 1 mM EDTA pH8, and 1 M Sorbitol), transferred to a 1 liter flask and shaken at 220 RPM for an incubation of 30 min at 30°C . The cells were then pelleted and resuspended with 625 μ l LiSORB, and held on ice while preparing the DNA.

The DNA was prepared for transformation by boiling 400 μ l 10 mg/ml Salmon sperm DNA for 10 min after which 500 μ l LiSORB was added and allowed to slowly cool to room temperature. DNA from the Mu T cell library was added (40-50 μ g) from a 1 mg/ml stock. The iced yeast culture was dispensed into 10 Eppendorf tubes with 120 μ l of prepared DNA. The

- 18 -

tubes were incubated at 30°C at 220 RPM. After 30 minutes, 900 μ l of 40% PEG₃₃₅₀ in 100 mM Li acetate, 10 mM Tris pH 8 and 1 mM EDTA pH 8 was mixed with each culture and returned to incubate for an additional 30 min. The samples were then pooled and a small aliquot (5 μ l) was removed
5 to test for transformation efficiency and plated on SC-Leu-Trp plates. The remainder of the cells were added to 100 ml SC-Leu-Trp-His media and grown for 1 hr at 30°C with shaking at 220 RPMS. Harvested cells were resuspended in 5.5 ml SC-Leu-Trp-His + 50 mM 3AT (3-amino triazole) media and 300 μ l aliquots plated on 150 mm SC-Leu-Trp-His + 50mM 3AT
10 and left to grow for 1 week at 30°C.

After four days, titer plates were counted and 1.1×10^5 colonies were screened. Large scale β -gal assays were performed on library plates and ten positive clones were isolated for single colonies. One of these colonies grew substantially larger than the rest, and was termed clone 11.1. Total
15 yeast DNA was prepared from these strains and leu2 plasmid DNA was isolated. The "rescued" plasmid was used to retransform the original y190A pAS1 AKAP 79 bait strain and y190a. Only clone 11.1 remained positive for β -galactosidase activity in y190A pAS1 AKAP 79. y190a containing pACT clone 11.1 remained white serving as a negative control.

20 Restriction digestion with endonuclease XhoI released a 2.3 Kb insert and the plasmid was sequenced in the forward and reverse directions. Reactions from the Dye Deoxy Terminator Cycle Sequencing Kit (Applied Biosystems, Inc. Foster City, CA) using symmetric polymerase chain reaction (PCR) on double stranded templates were analyzed on an ABI 373A
25 automated sequencer (Applied Biosystems, Inc.). Sequence from clone 11.1 revealed an open reading frame 487 aa long (SEQ ID NO:6) which was correctly fused to the Gal-4 activation domain of pACT. The NIH sequence database was searched and the sequence was found to be closely homologous to the human calmodulin dependent protein phosphatase, calcineurin.
30 Computer analysis between clone 11.1 and the human isoform A1 showed an

- 19 -

80% identity on the nucleic acid level and 93% identity on the amino acid level (Fig. 3). The first 10aa and an 18aa insert in the human sequence are not present in the mouse 11.1 sequence. Clone 11.1 is closely related to the mouse calcineurin A β sequence, but is distinctly dissimilar at the carboxy-terminus. Likewise the human calcineurin A1 and human calcineurin A2 isoforms are closely homologous but are distinct from each other at their 3' ends.

Specificity of the AKAP 79-calcineurin interaction was demonstrated by mating the calcineurin pACT containing strain with other unrelated bait strains. Crosses were performed as described above with strains containing pAS1 fused to RII (1-89), casein kinase 1, phosphodiesterase 32 (HDUN2) and AKAP Ht31. β -galactosidase activity was negative in all of these diploid strains.

Example 5

In order to further evaluate the nature of AKAP 79 interaction with clone 11.1, a series of calcineurin 11.1 deletion mutants was constructed and each plasmid tested in the dihybrid system.

Using the same 5' oligo (MH47) and four 3' oligos (MH48, MH49, MH50 and MH51), PCR reactions were set up to amplify regions of calcineurin 11.1 encoding amino acids 1-104, 1-204, 1-312 and 1-400 respectively. These fragments were digested with BglII and cloned into pACT. Orientation was confirmed by restriction digest mapping and PCR errors determined by automated sequencing. Plasmids determined to properly encode the desired deletion mutant were transformed into y190MATa and y190MAT α . Yeast strains were mated with y190apAS1 and y190apAS1 AKAP 79 along with the original clone pACT 11.1 encoding amino acids 1-487 in SEQ ID NO: 6. The resultant mating plate was filter assayed as described above, and it was observed that only fusions protein encoding either amino acids 1-400 or amino acids 1-487 were able to initiate transcription of

- 20 -

the reporter gene. The observation that a fusion protein containing amino acids 1-312 was unable to initiate transcription indicated that AKAP 79 binding requires residues between amino acids 313-400. This region has previously been demonstrated to include the FKBP/FK506 binding domain as well as the calcineurin B binding region [Husi, *et al.*, *J.Biol.Chem.*, 269:14199-14204 (1994)].

In order to more precisely define calcineurin amino acid sequences required for AKAP 79 binding, further deletion mutants were constructed and assayed for AKAP 79 binding. Expression constructs were generated using pACT encoding calcineurin 11.1 domains 332-441, 332-487 and 442-487. As before, each construct was sequenced and determined to express the correct mutant before transformation into the pAS1 AKAP 79 yeast strain.

Upon transformation, however, no reporter gene expression was detected indicating that the mutants were unable to interact with AKAP 79. One possible explanation for the lack of AKAP 79 binding is that secondary protein structure necessary for binding was lost with these truncated clones, or that some amino terminal sequence may also be required for binding.

Previous observations have indicated that interaction between immunophilin complex FKBP/FK506 with calcineurin A requires calcineurin B [Haddy, *et al.*, *FEBS* 314:37-40 (1992)]. In order to determine if calcineurin B endogenously expressed in yeast strain y190 participated in the observed AKAP 79/calcineurin A binding, a calcineurin B⁻ strain designated y153b (Mat a gal14 gal80 his3 trp1-901 ade2-101 ura3-52 leu2-3-112+URA::GAL-->lacZ, LYS2::GAL-->HIS3cnb1Δ1::ADE2) was utilized to eliminate the possibility of calcineurin B participation in calcineurin A/AKAP 79 binding. Initially y153b was transformed with pAS1 and pAS1 AKAP 79 and assayed for β-gal activity in the absence of a prey plasmid. No reporter gene expression was detected indicating that reporter gene expression following transformation with clone 11.1 would necessarily result from AKAP

- 21 -

79/11.1 binding. Plasmids pACT calcineurin 11.1 and pACT calcineurin 1-400 were then separately introduced into y153b1 pAS1 AKAP 79 through standard procedures. β -gal activity was observed in strains transformed with each plasmid indicating that the interaction between AKAP 79 and calcineurin A does not require calcineurin B. This result further suggests that binding of the immunophilin complex FKBP/FK506 to calcineurin A is distinct from AKAP 79 binding.

Example 6

In order to attempt to more precisely define the region of AKAP 79 binding on Calcineurin 11.1, an additional series of plasmids encoding deletion mutations, unique from those described above, or point mutations was constructed.

A. Terminal Deletions

This example demonstrates the interaction between AKAP 79 and calcineurin 11.1 requires residues 30-336 of calcineurin. Briefly, primers were designed to various regions of calcineurin 11.1 for use in PCR reactions to create specific N-terminal and C-terminal deletions as described in Table 1. PCR products were generated by mixing 1 μ g of each 3' and 5' primer with 200 μ g each dNTPs and 1 ng of plasmid template with PCR buffer #2 (containing 20 mM Tris-HCl, pH 8.75, 10 mM KCl 10 mM $(\text{NH}_4)_2\text{SO}_4$, 2 mM MgSO_4 , 0.1% Triton X-100, and 100 μ g/ml BSA) (Stratagene) and 2.5 units *Pyrococcus furiosus* (Pfu) DNA polymerase (Stratagene) in a 100 μ l reaction volume. Thirty cycles were carried out, each one minutes at 95°C, two minutes at 50°C and four minutes at 72°C. Amplification products were purified and cloned in a BglII site of pACT. Resultant constructs were analyzed for PCR errors and orientation by sequencing as previously described.

Each construct was individually transformed into y190 α , y190a pASI APAK79 and y153b pASI AKAP 79 yeast strains, each described above

- 22 -

in Example 4A, and β -galactosidase filter assays were performed also as previously described. Results using a first set of vectors encoding C-terminal deletions defined an area between amino acid 312-400 required for AKAP 79 binding. Positive filter assays from the y153b pAS1 APAK79 transformants also confirmed that calcineurin B was not required for AKAP 79 binding.

Previous studies have indicated that binding of calcineurin B requires amino acids 348, 349, 355 and 356 [Watanabe, *et al.*, *J.Biol.Chem.* 270:456-460 (1995)], the calcineurin autoinhibitory domain includes amino acids 442-487, and FKBP/FK506 binding requires amino acids 350, 353 and 359 [Kawamura and Su, *J.Biol.Chem.* 270:15463-15466 (1995)]. Additional calcineurin 11.1 constructs encoding further C-terminal deletions indicated that the calcineurin 11.1/AKAP 79 binding required amino acids 1-336. These deletions demonstrate the calmodulin binding domain [WHERE IS THIS DOMAIN?], the autoinhibitory domain and the calcineurin B binding domain are not required for AKAP 79 and calcineurin A to form a complex.

Binding results for all deletions are presented in Table 1. Amino deletions indicated that at least one area required for AKAP 79 binding lies between residues 30-99. As before, y153b pAS1 AKAP 79 transformants expressing N-terminal deletions did not require calcineurin B for binding.

- 23 -

Table 1
AKAP 79/Immunophilin Binding to Calcineurin Deletion Mutants

	Calcineurin Deletion (designation by primers* used to construct expression plasmid)	Amino Acid Sequence	AKAP 79 Binding	Immunophilin Binding
5	MH52-MH58	1-487	+	N.D.
	MH52-MH48	1-400	+	N.D.
	MH52-MH49	1-312	-	N.D.
	MH52-MH50	1-204	-	N.D.
10	MH52-MH51	1-104	-	N.D.
	MH66-MH58	332-487	-	N.D.
	MH59-MH58	441-487	-	N.D.
	MH66-MH57	332-441	-	N.D.
	MH52-MH75	1-375	+	+
15	MH52-MH74	1-354	+	-
	MH76-MH75	30-375	+	+
	MH77-MH75	98-375	-	-
	MH52-MH93	1-347	+	N.D.
	MH52-MH94	1-340	+	N.D.
20	MH52-MH95	1-330	-	N.D.
	MH52-MH96	1-320	-	N.D.
	MH52-MH107	1-338	+	N.D.
	MH52-MH108	1-336	+	N.D.
	MH52-MH109	1-334	-	N.D.

- 24 -

Calcineurin Deletion (designation by primers* used to construct expression plasmid)	Amino Acid Sequence	AKAP 79 Binding	Immunophilin Binding
MH52-MH110	1-332	-	N.D.
MH52-MH111	1-335	-	N.D.

* Primers used to construct expression plasmids

5 MH48 (SEQ ID NO: 10) 5'-GTATTAGCAGGAGATCTTCCTACTTC-3'
 MH49 (SEQ ID NO: 11) 5'-GTGTGTGTAGATCTGGTGAAAGTCC-3'
 MH50 (SEQ ID NO: 12) 5'-ATTGTAGAGATCTAAGTAATTAGGTGCCG-3'
 MH51 (SEQ ID NO: 13) 5'-GCCAATTGCTCAGATCTTGTTCCTATG-3'
 MH52 (SEQ ID NO: 14) 5'-GGAAATTCGGATCCTCGAGAGATCTCGCCG-3'
 10 MH57 (SEQ ID NO: 15) 5'-CCACTTTGAGATCTCTACCGTCCTCCAGCC-3'
 MH58 (SEQ ID NO: 16) 5'-CCCTGAGATCTTCAGCTGCTAAGAC-3'
 MH59 (SEQ ID NO: 17) 5'-GGCTGAGATCTGGCAGACCTTGCAAAGTGG-3'
 MH66 (SEQ ID NO: 18) 5'-GTGATGAAGATCTTACAGTTTAATTGCTCTCC-3'
 MH74 (SEQ ID NO: 19) 5'-TTCTCCAGATCTTGGTAAGGACCATG-3'
 15 MH75 (SEQ ID NO: 20) 5'-CACCTTCTGTAGATCTTTCATCATCAGAAC-3'
 MH76 (SEQ ID NO: 21) 5'-CATCGGCAGATCTCTGAAGAAGTG-3'
 MH77 (SEQ ID NO: 22) 5'-CCATGGCCAATTTTAGATCTCGATGAAAC-3'
 MH93 (SEQ ID NO: 23) 5'-GGACCATGAGATCTAATCCATAAAATTGGG-3'
 MH94 (SEQ ID NO: 24) 5'-AAATGGGAGATCTAATAAGGATGTGGAGAGC-3'
 20 MH95 (SEQ ID NO: 25) 5'-GGAGAGCAATTAAGATCTAAATGTTTCATCAC-3'
 MH96 (SEQ ID NO: 26) 5'-TTTTCATAGATCTATACAAGCAGCTTT-3'
 MH107 (SEQ ID NO: 27) 5'-CAACCAGATCTAATGTGGAGAGCAATTAAGTGTGCG-3'
 MH108 (SEQ ID NO: 28) 5'-CCAATAAGAGATCTAAGAGCAATTAAGTGTGCG-3'
 MH109 (SEQ ID NO: 29) 5'-TGTGAGATCTAATTAAGTGTGCAATGTTTCATCAC-3'
 25 MH110 (SEQ ID NO: 30) 5'-GGAGAGCAGATCTACTGTGCAATGTTTCATCAC-3'
 MH111 (SEQ ID NO: 31) 5'-AAGGATAGATCTAGCAATTAAGTGTGCAATGTTTCATCAC

B. Point Mutations

In order to evaluate precisely which amino acids participate in AKAP 79 binding, calcineurin 11.1 point mutations were created using a PCR based strategy. Three alanine mutants, Cys³³⁵→Ala Ser³³⁶→Ala and
 30 Pro³³⁹→Ala, were generated and assayed for modulation of AKAP 79 binding in the dihybrid system. None of these mutants have prevented AKAP 79 to bind to calcineurin indicating that modification of these residues alone is insufficient to disrupt AKAP 79 binding.

- 25 -

Example 7

Additional screening using pACT Mu T-cell library DNA and the pASI AKAP 79 bait strain was performed in order to identify other AKAP 79 binding proteins by the protocol described above. Results from screening approximately 211,000 colonies gave one positive clone designated pACT 2-1 which remained positive following rescue and retransformation. The library sequence was removed from the plasmid with XhoI digestion and shown to be a 1200 bp insert. Sequencing and a subsequent data base search indicated that the clone had 91% identity with rat type 1 α regulatory subunit of protein kinase A (RI).

The library was rescreened using the same AKAP 79 bait and fifteen positives were detected from approximately 520,000 transformants. Of these fifteen, eleven were found to be homologous to the rat regulatory subunit type I of PKA. Each of these isolates were fused to the 5' untranslated region of RI and remained open through the initiating methionine. Based on restriction digest analysis and sequencing data, nine individual clones were isolated, including the original pACT 2-1 isolate.

These results are the first demonstration of an anchoring protein which binds both RII and RI regulatory subunits of PKA, which is unexpected in view of structurally dissimilar primary structures between the two subunits.

In order to attempt to further define the sequence of interaction between RI and AKAP 79, and to determine if the interaction is unique to AKAP 79, new yeast strains were developed. Utilizing a BgIII site within the first 400 bp of RI, a fragment encoding amino acids 1-80 was isolated from pACT72 and ligated to pAS1 and pACT. Orientation was confirmed by restriction digest analysis. Using standard yeast transformation procedures, plasmid DNA was introduced into y190 MAT a and the transformed yeast assayed for β -gal activity. The truncated RI fusion product was determined to be unable to promote expression of the reporter gene. The transformed

- 26 -

strains were subsequently utilized in a series of experiments to determine if the truncated RI form would interact with AKAP 79.

Reporter gene expression was observed in the doubly transform yeast strain indicating that RI/AKAP 79 binding was effected via the first 80
5 amino acids of RI.

Finally, in an effort to determine if the ability to bind both RI and RII subunits was unique to AKAP 79, a human thyroid AKAP [Carr, *et al.*, *J.Biol.Chem.* 267:133376-133382 (1992)], the gene product of pACT Ht31, was assayed by the dihybrid screen with the above described truncated
10 RI peptide containing amino acids 1-80 and encoded on plasmid pAS1(1-80). The observed Ht31/RI binding, in combination with a previous observation that Ht31 binds RII indicated that anchoring protein binding with both RI and RII is not unique to AKAP 79.

Example 8

15 In view of the fact that AKAP 79 was shown to bind both RI and RII subunits of PKA, a scintillation proximity screening technique was developed to identify specific inhibitors that disrupt localization of PKA by interfering with AKAP 79 binding to PKA.

Initially, a thioredoxin (TRX)-AKAP 79 fusion protein
20 expression plasmid was constructed. See, generally, LaVallie, *et al.*, *BIO/TECHNOLOGY* 11:187-193 (1993). Briefly, a *XbaI/HindIII* thioredoxin fragment was subcloned into pUC19 containing a lac Z gene and a *tacZ* promoter. The resulting plasmid was designated TRX F/S pUC19. In order to insert an AKAP 79 encoding sequence into TRX F/S pUC19, an *NcoI* site
25 was created with an oligonucleotide (SEQ ID NO: 32) having terminal *SpeI* and *HindIII* sequences. Following *SpeI/HindIII* digestion, the oligonucleotide was inserted into the vector and an *NcoI/XhoI* fragment encoding AKAP 79 was ligated in frame with the thioredoxin gene. The fusion protein was expressed in *E.coli* and immobilized on 96-well ScintiStrip plates (Wallac,

- 27 -

Turku, Finland) which contained a scintillator embedded in the solid support. The plates were precoated with a rabbit anti-mouse antibody which was used to immobilize a mouse monoclonal antibody immunospecific for TRX. The TRX-AKAP 79 fusion protein was then captured on the plates via the anti-
5 TRX antibody, and ^3H -RII was added to the plates in the presence or absence of a reference inhibitor, for example, unlabeled RII. When ^3H -RII bound to AKAP 79, the label was brought sufficiently close to the support-embedded scintillator, resulting in emission detected in a MicroBeta scintillation counter.

Results from this assay indicated that unlabeled RII and the
10 Ht31 peptide, described above, were able to inhibit AKAP 79/RII binding with an IC_{50} of 1 mM and 50 nM, respectively. These results are similar to the reported values of other anchoring proteins [Carr, *et al.*, *J. Biol. Chem.* 267:13376-13382 (1992)]. The proline-substituted Ht31 peptide, also described above, did not block AKAP 79/RII binding. Because these results
15 were consistent with those observed in previous Western blotting and overlay assays, it is presumed that this technique will permit rapid screening of potential inhibitors of AKAP 79/RII binding, as well as inhibitors of AKAP 79 binding to other known physiological partners, for example calcineurin and protein kinase C.

Example 9

20 This example demonstrates that association of PKA with an anchoring protein in T cells modulates the activity of PKA on NFAT activation thus modulating interleukin 2 production.

The expression of the IL-2 gene is tightly linked to T cell
25 activation. IL-2 transcription was studied following activation with PMA and ionomycin. These two agents are known respectively to potentiate protein kinase C and calcium second messenger responses (including activation of CaN). Protein kinase C activates the Ras-Raf-1-Mek-MAP Kinase pathway that participates in induction of the nuclear component of NFAT. The

- 28 -

increased calcium concentration activates calcineurin that, in turn, activates the cytoplasmic component of NFAT and allows translocation to the nucleus. This activation of the NFAT components induces IL-2 gene expression. To quantitate transcription, a Jurkat T cell line (NFATZ) was stably transfected with a vector containing 3 tandem copies of the NFAT-binding site, and the minimal IL-2 promoter fused to the lacZ gene encoding β -galactosidase (β -gal). Quantitation of IL-2 transcription was achieved through fluorescence-activated cell sorter (FACS) analysis of β -gal activity.

Typically, 1×10^6 NFATZ cells in 1 ml of culture medium were pre-incubated for 60 min at 37°C with varying concentrations of cyclosporin, and myristilated peptides including amino acids 81-108 of AKAP 75 (SEQ ID NO:8; described in Glantz et al., *J. Biol. Chem.*, 268:12796-12804 (1993), incorporated herein by reference), PKI (a PKA inhibitor peptide (GRRNAIHDI-SEQ ID NO:5)), and a peptide of Ht31 (SEQ ID NO:9; amino acids 493-515 of the full length Ht31 protein described in Carr et al., *J. Biol. Chem.*, 267:13376-13382 (1992), incorporated herein by reference, that blocks anchoring protein interaction with the RII subunit of PKA). Each of the peptides was myristilated as described in Eichholtz et al., *J. Biol. Chem.*, 268:1982-1986 (1993).

In the experiments with cyclosporin, PKI (SEQ ID NO:5), and an Ht31 peptide (SEQ ID NO:9), incubation with cyclosporin or the respective peptides was followed by a further 30 min incubation with forskolin (25 μ M) and iso-butyl-methyl-xanthine (IBMX; 0.1 mM). Incubation with forskolin/IBMX elevates intracellular cAMP concentrations (Fig. 4), thereby activating PKA. Finally, phorbol 12-myristate 13-acetate (PMA) (10 ng/ml) and ionomycin (2 μ M) were added and incubations continued for 4 hr. Controls were incubated with PMA/ionomycin alone or forskolin/IBMX and PMA/ionomycin under conditions as described above. During the last 20 min of the PMA/ionomycin incubation, chloroquine (300 μ M) was added to inhibit endogenous lysosomal β -gal activity. The cells were spun out and

- 29 -

resuspended in 50 μ l of culture medium to which 50 μ l of fluorescein di- β -D-galactopyranoside (FDG) was added (0.1 mM final concentration; Molecular Probes). This osmotic shock procedure continued for 75 secs before returning the cells to isotonic conditions by the addition of 1 ml cold FACS buffer (including chloroquine). lacZ β -gal activity was measured by flow cytometry configured for fluorescein analysis.

Figs. 5A-5H illustrated the results of this experiment. Figs. 5A and 5B are FACS plots showing the background fluorescence of the assay with and without added dye. Fig. 5C shows that PMA/ionomycin treatment of NFATZ Jurkat cells induced a 6-7 fold increase in β -gal activity. Cyclosporin (CsA) completely abolished this activity as would be expected for the important signaling role of CaN in IL-2 transcription (Fig. 5D). The myristilated AKAP 75 peptide (SEQ ID NO:8) when used at 10 μ M in the medium was found to reduce PMA/ionomycin induced β -gal activity by 40-50%.

Fig. 5E shows that forskolin and IBMX reduced PMA/ionomycin induced β -gal activity by approx. 50%. This blockade was completely reversed by both 100 μ M myristilated PKI peptide (SEQ ID NO:5) and 100 μ M myristilated Ht31 peptide (SEQ ID NO:9) (Figs. 5F and 5G). Fig. 5H shows that a myristilated Ht31 peptide with a proline substitution which is known to render the peptide inactive in blocking PKA anchoring did not affect the forskolin/IBMX blockade. These results demonstrate the importance of PKA and its localization through an anchoring protein in regulating IL-2 gene expression. As described above, interfering with PKA activity or localization may be used for enhancing the immune response, activating T cells for selective clonal expansion or investigation of early events of T cell activation.

- 30 -

Example 10

Two additional unique isolates, pACT 59 and pACT 74, were identified which encoded for the same region for another protein. The sequences for these clones are set out in SEQ ID NOs: 33 and 34, respectively. Blast search results indicated significant amino acid homology with three genes products of unknown function: *C. elegans* (a 319 amino acid protein, designated No. U00032 in the data base listing), human fetal brain expressed sequence tag (a 97 amino acid protein, designated T08697), and HL60 expressed sequence tag (a 90 amino acid protein, designated D20731). Homology was also found between an *S. pombe* gene product designated PAD 1⁺ (a 308 amino acid protein, designated D31731) which has been shown to be a positive regulator of PAP1⁺, an AP-1 like transcription factor.

In addition, two other positive clones were detected in this screen; pACT 36, which encoded a 143 amino acid open reading frame correctly fused to Gal4, and pACT 60, which encoded a slightly shorter region resulting from an apparent deletion. Sequences for these clones are set out in SEQ ID NOs: 35 and 36, respectively. The two isolates were unique from each other and showed no identity with any known sequence in the NIH database.

20

Example 11

Previous work suggests that AKAP 79 is a multifunctional anchoring protein which is able to associate with at least two signaling enzymes; PKA and the Ca²⁺/calmodulin-dependent phosphatase calcineurin (CaN). Each signaling enzyme binds to a distinct region of the anchoring protein and each enzyme is inhibited when anchored. In addition, it has been demonstrated that Ca²⁺/phospholipid-dependent protein kinase C (PKC) binds to AKAP 79 as well, in a region distinct from that of PKA and CaN. Like PKA and CaN, activity of PKC is inhibited by its association with the anchoring protein. The PKC-binding site is contained within the first 75

- 31 -

residues of the anchoring protein and peptide studies have shown that a fragment containing residues 31-52 of AKAP 79 inhibit PKC activity. Furthermore, evidence suggests calmodulin (CaM) binding to the anchoring protein may release PKC activity suggesting competition for an AKAP 79 sequence. In order to more fully characterize PKC interaction with AKAP 79, experiments were undertaken to characterize the PKC-binding site, isolate the PKC/AKAP complex from bovine brain and determine if CaM is a physiological regulator of PKC/AKAP 79 interaction.

A PKC overlay was initially performed on bovine brain lysates using rabbit brain PKC as a probe. PKC-binding was detected with a monoclonal antibody (M7) which recognizes the PKC α and β isoforms. Several PKC-binding proteins were detected ranging in size from 50-300 kDa and included a protein that migrated with a similar mobility as a prominent 75 kDa RII-binding protein. Control experiments confirmed that PKC-binding was specific and could be detected only in the presence of 1.2 mM CaCl₂ and 20 μ g/ml phosphatidylserine, and when PKC was added to the reaction mixture.

In order to determine if the 75 kDa protein identified may be the bovine homolog of AKAP 79, the PKC overlay assay was used to probe AKAP 79 and related fragments. Briefly, proteins were separated by SDS-polyacrylamide electrophoresis (SDS-PAGE) and blotted to nitrocellulose following standard protocols. Samples were blocked in Blotto [1 mg/ml bovine serum albumin (BSA), 5% dry milk in Tris-buffered saline (TBS)] and incubated for one hour at room temperature in assay buffer [TBS containing 1 mg/ml BSA, 1.2 mM calcium, 1 mM EGTA, 20 μ g/ml phosphatidylserine (PS), 2 μ g/ml leupeptin, 2 μ g/ml pepstatin and 3 μ g/ml of partially purified rabbit brain PKC]. Bound PKC was detected with monoclonal antibody M7, which recognizes both PKC α and β , following standard chemiluminescent detection methods.

- 32 -

PKC bound to the full-length recombinant AKAP 79 protein, and recombinant fragments encompassing the first 75 residues of the protein bound PKC, but C-terminal fragments covering the CaN and RII-binding regions did not. Control experiments demonstrated that ^{32}P -radiolabeled RII
5 bound to both full-length AKAP 79 and the C-terminal fragments. These results showed that AKAP 79 is a PKC-binding protein and that the principle binding site resides within the first 75 amino acids of the protein.

Previous studies on PKC-binding proteins have suggested that basic and hydrophobic regions from PKC-binding sites participate in formation
10 of a phospholipid bridge with the enzyme. The first 75 residues of AKAP 79 contain a basic and hydrophobic region between positions 31-52 and several lines of evidence suggest that this region is a principle site of contact with PKC. A synthetic peptide to residues 31-52 blocked PKC/AKAP 79 interaction as assessed by the overlay assay.

15 In order to assess the ability of these peptides to modulate PKC activity, the following assay was performed in the presence and absence of AKAP 79 peptide fragments. PKC [50 nM dissolved in 50 mM tris-HCl (pH 7.4), 5 mM MgCl_2 1.2 mM CaCl_2 , 1 mM DTT, 1 mM EGTA and 100 $\mu\text{g/ml}$ PS] was incubated with EGF receptor peptide substrate (5 μM) at 30°C for
20 five minutes. Phosphorylation reaction was initiated by addition of 100 μM ^{32}P -ATP (500 cpm/pmol) and the reaction allowed to proceed for ten minutes at 30°C. Aliquots of reaction mixture were removed and spotted into P81 filter paper and the reaction terminated by washing the filter paper with excess
25 75 mM phosphoric acid (three washes for three minutes each). After a final wash in ethanol, the p81 filters were dried and radioactivity was measured by liquid scintillation counting.

The peptide containing residues 31-52, as well as a recombinant fragment to the first 75 amino acids of AKAP 79, were potent inhibitors of PKC activity with IC_{50} of 2 μM and 25 nM, respectively. More detailed
30 kinetic analysis showed that the AKAP 79 31-52 peptide exhibited mixed

- 33 -

inhibition of PKC activity with a K_i of $1.411 \pm 0.28 \mu\text{M}$ using the epidermal growth factor (EGF) receptor peptide as a substrate. In addition, this region also resembles a CaM-binding domain, and incubation of the recombinant 1-75 fragment or the 31-52 peptide with CaM ($15 \mu\text{M}$) prevented inhibition of PKC in the presence of excess Ca^{2+} . Since AKAP 79 is a CaM-binding protein, these findings suggest that Ca^{2+} /CaM may regulate PKC binding to the anchoring protein.

Combined, these results suggest that PKC associates AKAP 79 *in vitro*, the PKC-binding site is contained within the first 75 residues of AKAP 79, and peptides encompassing residues 31-52 inhibit PKC activity. Results also suggest that PKC/AKAP 79 interaction may be regulated by CaM as incubation with excess Ca^{2+} /CaM prevents inhibition of PKC by the 31-52 peptide (Fig. 3). In order to more fully understand the nature of AKAP 79/PKC interaction, experiments were designed to 1) identify residues important for PKC binding to AKAP 79, 2) isolate a PKC/AKAP 79 complex from cells and 3) establish whether CaM regulates PKC/AKAP 79 interaction.

Sequence analysis of several PKC-binding proteins has suggested that a highly positive surface charge may be required for association with the PKC. Consistent with this hypothesis are previous results wherein a peptide fragment of AKAP 79 amino acids 31-52 which encompasses a cluster of basic and hydrophobic residues inhibits PKC activity (K_i of $1.4 \pm 0.28 \mu\text{M}$) and a recombinant fragment to this region is an even more potent inhibitor of the kinase ($\text{IC}_{50} = 25 \pm 5 \text{ nM}$). In order to assess the role of basic side-chains located between residues 31-52 of AKAP 79 as determinants for PKC inhibition, a family of AKAP 79 mutants are generated in a recombinant AKAP 79 polypeptide containing amino acids 1-75, and PKC binding properties of each mutant assayed by the overlay method and for changes in inhibitory potency toward PKC βI .

Five AKAP 79 mutants are constructed in which clusters of basic residues are replaced with alanine. Given the high density of positive

- 34 -

charge, it is likely that simultaneous substitution of several basic side chains will be necessary before significant changes in PKC-binding affinity are recorded. Therefore, multiple basic residues are substituted. Point mutants in the AKAP 79 sequence are created by alanine scanning mutagenesis using the methods described by Hausken, *et al.* [*J.Biol.Chem.* 269:24245-24251 (1994)] Each AKAP 79 protein is expressed as a His-tag fusion protein and purified to homogeneity by nickel affinity chromatography. The alanine mutant peptides are shown below. SEQ ID NO: 37 is the native AKAP 79 sequence.

- 10 AKAP 79 (37-50) FXRRKKAALAPK (SEQ ID NO: 37)
- AKAP 79 AA38,39 FAARKKAALAPK (SEQ ID NO: 38)
- AKAP 79 AAA40-42 FKRAAAAALAPK (SEQ ID NO: 39)
- AKAP 79 4A38-42 FAAAAAAALAPK (SEQ ID NO: 40)
- AKAP 79 AA45,50 FKRRKKAALAPA (SEQ ID NO: 41)
- 15 AKAP 79 A37-50 FAAAAAAAALAPA (SEQ ID NO: 42)

The PKC β I protein is expressed in baculovirus and monoclonal antibodies M4 and M7 are used to detect PCK α and β isoforms by the following method.

In addition, each mutant AKAP 79 fragment mutant is assayed for its ability to inhibit PKC by the method described above.

- 20 Because preliminary data suggests that PKC and AKAP 79 associate *in vitro*, it should be possible to isolate the AKAP 79/PKC complex from cells if the same or similar binding occurs *in vivo*. In order to attempt to isolate PKC/AKAP 79 binary complex, or a PCK/AKAP 79/CaN ternary complex from bovine brain, two independent biochemical approaches are
- 25 employed that previously were successful for isolating an *in vivo* AKAP 79/CaN complex. The techniques are briefly described below.

Initial studies involve immunoprecipitation of the APAK 79 homolog, AKAP 75, from bovine brain, using monoclonal antibody MC16

- 35 -

generated against AKAP 79. Co-purification of PKC in the immunoprecipitates is detected by Western blot with rabbit polyclonal antisera that recognizes the predominant brain PKC isoforms α β I, β III, and γ . Alternatively, PKC is immunoprecipitated from bovine brain extracts with the monoclonal antibody M7 which recognizes the brain PKC α and β isoforms and co-purifying AKAP 75 is detected by RII overlay or Western blot. Finally, identical samples immunoprecipitated with anti-PKC antibodies are probed for CaN with monoclonal antibody C24 that recognizes the bovine CaN A subunit. These experiments may establish whether a ternary complex of APAK 79/PKC and CaN is formed.

Alternatively, affinity purification is performed in order to isolate a ternary complex of RII, AKAP 79 and PKC from bovine brain. The R subunit of PKA is purified by affinity chromatography on cAMP-agarose and the eluate screened for the presence of PKC and AKAP by Western blots with the M7 and MC16 monoclonal antibodies, respectively. Since recombinant AKAP 79 and PKC do not bind cAMP-agarose, detection of either protein in the cAMP eluate confirms the formation of a complex between both kinases and the anchoring protein. Confirmation of a ternary complex is achieved by elution of PKC and AKAP 79 from cAMP-agarose with excess anchoring inhibitor peptide. This peptide has previously been shown to displace the AKAP/CaN complex from RII immobilized on cAMP-agarose.

Example 12

The previous demonstration that AKAP 79 binds calcineurin is relevant in view of the fact that calcineurin is the target of two potent and clinically useful immunosuppressive, cyclosporin and FK506, both of which inhibit calcineurin activity. As described below, both cyclosporin and FK506 are useful in treatment of a variety of diseases, but have significant limiting side effects. Presumably, factors which modulate anchoring

- 36 -

protein/calcineurin binding may ultimately modulate calcineurin activity in a manner similar to the activities of cyclosporin or FK506. Identification of such a modulator, particularly with fewer side effects than those observed with other immunosuppressants, would possibly have widespread therapeutic use
5 treatment of a multitude of disease currently treated with cyclosporin or FK506.

Numerous clinical indications of cyclosporin and FK506 have been reported. For example, cyclosporin has defined the standard for post-transplant immunosuppression, making possible liver, lung, intestine, and
10 pancreas transplants, even though FK506 is generally believed to be a stronger immunosuppressive. Transplant patients who do not tolerate or fail on either cyclosporin or FK506 are sometimes successfully changed to the other drug.

As another example, inflammatory bowel disease (IBD) is a common term for two diseases having different clinical appearances, Crohn's disease and ulcerative colitis (UC). Cyclosporin has been successfully used
15 to treat Crohn's disease, with statistically significant results of treatment having been demonstrated in at least one index of disease activity [Brynskov, *Dan.Med.Bull.* 41:332-344 (1994)]. Other indices, however, that correlate best with resolution of acute exacerbations showed non-significant trends
20 toward improvement. Cyclosporin has also shown activity in severe acute steroid-resistant UC (the data are not significant as the trial was stopped for ethical reasons). Another trial of patients with sclerosing cholangitis and UC demonstrated borderline significance toward a milder course of UC. Relapse was common after withdrawal and treatment has been limited by concern for
25 toxicity [Choi and Targan, *Dig.Dis. and Sci.* 39:1885-1892 (1994)]. In addition, other immunosuppressives have been used successfully in IBD, such as methotrexate, azathioprine, and 6-MP.

As another example, cyclosporin has been demonstrated to be effective in treating rheumatoid arthritis in several trials when used as a
30 second or third line therapy of the disease, i.e., in patients that have failed

- 37 -

other established therapies and have severe disease. In these trials, cyclosporin was found to be generally as effective and toxic as other second-line agents, such as gold, antimalarials, azathioprine, D-penicillamine, and methotrexate [Wells and Tugwell, *Br.J.Rheum.*, 32(suppl 1):51-56 (1993);
5 Forre *et al.*, *Arth.Rheum.*, 30:88-92 (1987)]. The trials only report treatment of "very severe, refractory active RA" because of cyclosporin's "potentially irreversible toxicity" [Dougados and Torley, *Br.J.Rheum.*, 32(suppl 1):57-59 (1993)]. The renal toxicity is thought to have been primarily mediated
10 through renal vasoconstriction that exacerbates NSAID nephrotoxicity and renal disease inherent in rheumatoid arthritis [Leaker and Cairns, *Br.J.Hosp.Med.*, 52:520-534 (1994); Sturrock *et al.*, *Nephrol.Dial.Transplant*, 9:1149-1156 (1994); Ludwin and Alexopolulou, *Br.J.Rheum.*, 32(suppl 1):60-64 (1993)]. About 10% of renal biopsies from RA patients treated with cyclosporin showed morphological features of cyclosporin toxicity
15 [International Kidney Biopsy Registry of Cyclosporin in Autoimmune Diseases, *Br.J.Rheum.*, 32(suppl 1):65-71 (1993)].

As still another example, cyclosporin has been reported to be effective for treatment of steroid-dependent asthma. In one trial, a small number of patients were randomized to cyclosporin or placebo, and the
20 cyclosporin group exhibited increased airflow and FVC as well as fewer rescue courses of prednisolone.

As another example, cyclosporin was shown to be effective in the treatment of steroid-dependent minimal change disease nephrotic syndrome. Patients in this trial were shown to have lower steroid
25 requirements on low dose cyclosporin, but all relapsed when cyclosporin was discontinued. Steroid-resistant forms of nephrotic syndrome have only a 20-30% response rate to cyclosporin [Meyrier, *Nephrol.Dial.Transplant*, 9:596-598 (1994); Hulton *et al.*, *Pediatr.Nephrol.*, 8:401-403 (1994)].

With regard to treatment of systemic lupus erythematosus
30 (SLE), one study reported significant decrease of SLE activity indices in a

- 38 -

prospective non-randomized, non-controlled study [Tokuda *et al.*, *Arthr.Rheumat.*, 37:551-558 (1994)]. Other studies, however, have not demonstrated efficacy in SLE.

As another example, cyclosporin has been shown to induce
5 remission in insulin-dependent diabetes mellitus when instituted early after
initial presentation. Remissions averaged about one year, although some were
extended up to 850 days [Jenner *et al.*, *Diabetologia*, 35:884-888 (1992);
Bougnères *et al.*, *Diabetes*, 39:1264-1272 (1990)]. No long-lasting effect of
cyclosporin was noted in extended follow-up of one study [Martin *et al.*,
10 *Diabetologia*, 34:429-434 (1991)]. In another study, however, renal function
deteriorated during treatment for 12-18 months and did not return completely
to placebo level indicating that some chronic renal injury may have occurred
[Feldt-Rasmussen *et al.*, *Diabetes Medicine*, 7:429-433 (1990)]. Earlier
intervention would be needed to enhance the effect of immunosuppressive
15 therapy on the course of insulin-dependent diabetes mellitus. Some
investigators are screening first degree relatives and successfully
prophylactically treating those with diabetic markers [Elliott and Chase,
Diabetologia, 34:362-365 (1991)].

As still another example, psoriasis has been effectively treated
20 by cyclosporin [Cuellar *et al.*, *Balliere's Clin.Rheum.*, 8:483-498 (1994); Ellis
et al., *JAMA* 256:3110-3116 (1986)]. High dose therapy was effective for
treatment of psoriatic arthritis, a particularly severe form of destructive
arthritis, and discontinuation of therapy was generally followed by
exacerbation of skin and joint disease. In view of the potential side effects
25 and the need for continuous long term treatment, cyclosporin is only indicated
for refractory psoriatic arthritis that is not adequately treated by other means.

In addition, cyclosporin has been demonstrated to be effective
for treatment of severe atopic dermatitis in placebo-controlled and double-
blinded studies [Van Joost *et al.*, *Br.J.Derm.*, 130:634-640 (1994); Cooper,
30 *J.Invest.Derm.*, 102:128-137 (1994)]. Side effects of nausea, abdominal

- 39 -

discomfort, paresthesias, cholestasis, and renal insufficiency from the drug were preferred by patients to their untreated disease. Another randomized double-blind, placebo-controlled study found that cyclosporin treatment significantly increased the quality of life for patients with severe atopic dermatitis [Salek *et al.*, *Br.J.Derm.*, 129:422-430 (1993)]. Skin lesions quickly relapsed following cessation of cyclosporin, but quality of life remained improved.

As still another example, cyclosporin has been used in treatment of chronic dermatitis of the hands, a disease with a reported prevalence of 4-22%, and typically treated with topical steroids to which many patients, however, do not respond. Low dose cyclosporin has been shown to effectively treated 6/7 patients in an open study [Reitamo and Granlund, *Br.J.Derm.*, 130:75-78 (1994)]. Approximately half of the patients relapsed after cyclosporin was discontinued.

As still another example, cyclosporin has been utilized in treatment of urticaria and angioedema, idiopathic skin diseases that present as hives and subcutaneous swelling. The pathology is related to mast cells, and treatment is often ineffective. IN one trail, three patients with refractory urticaria and angioedema were treated with cyclosporin and all symptoms resolved within one week [Fradin *et al.*, *J.Am.Acad.Derm.*, 25:1065-1067 (1991)]. All patients had to stop therapy because of side effects, and symptoms recurred after therapy was discontinued.

With regard to other rheumatological diseases, studies report effective cyclosporin treatment of other less common autoimmune diseases, including Behcet's Disease [Pacor *et al.*, *Clin.Rheum.*, 13:224-227 (1994)], Wegner's Granulomatosis [Allen *et al.*, *Cyclosporin A Therapy for Wegner's Granulomatosis* in ANCA-Associated Vasculitides: Immunological and Clinical Aspects, Gross ed. Plenum Press (1993)], and immune-mediated thrombocytopenia [Schultz *et al.*, *Blood* 85:1406-1408 (1995)].

- 40 -

In many of the trials described above, use of cyclosporin or FK506 was associated with many undesired side effects. In general, increased risk of infection and malignancy are associated with general immunosuppression, and it is unlikely that an anchoring protein-related immunosuppressive would not have similar risks. Other side effects may be avoided or reduced, however, by anchoring protein tissue specificity. The most common serious side effect of both cyclosporin and FK506 is nephrotoxicity, which at least to some degree is dose related and occurs in most patients, generally in the form of a decrease in the glomerular filtration rate during treatment. This side effect, however, is at least partially reversible when the drug is discontinued [Leaker and Cairns, *supra*]. Typically, progressive renal insufficiency does not develop, although more follow-up is needed for definitive evaluation. Chronic injury has also been observed in patients receiving low dose cyclosporin (3-4 mg/kg/d), about 40% of biopsies of these patients showed changes of interstitial fibrosis, tubular atrophy, and arteriolopathy [Svarstad *et al.*, *Nephrol.Dial.Transplant*, 9:1462-1467 (1994); Young *et al.*, *Kidney International*, 46:1216-1222 (1994)]. Changes in endothelial cells were also apparent in histological sections [Kahan, *N.Engl.J.Med.*, 321:1725-1748 (1989)]. The nephrotoxicity was postulated to have resulted primarily due to arteriolar vasoconstriction and chronic low-grade ischemia [Leaker and Carins, *supra*], although the drugs were also shown to be directly toxic to tubular cells and vascular interstitial cells [Platz *et al.*, *Transplantation*, 58:170-178 (1994)]. Some reports indicate that the incidence and severity of nephrotoxicity may be slightly higher with FK506 [Platz *et al.*, *supra*].

Another reported significant toxicity of both cyclosporin and FK506 was neurotoxicity, with clinical manifestations including seizures, confusion, blindness, coma, headache, ataxia, Parkinson's syndrome, paresthesias, psychosis, focal deficits, akinetic mutism, tremors, neuropathy, and sleep disturbances [Shimizu *et al.*, *Pediatr. Nephrol.*, 8:483-385 (1994);

- 41 -

Wilson *et al.*, *Muscle and Nerve*, 17:528-532 (1994); Reece *et al.*, *Bone Marrow Transpl.*, 8:393-401 (1991); Eidelman *et al.*, *Transpl. Proc.*, 23:3175-3178 (1991); de Groen *et al.*, *N.Engl.J.Med.*, 317:861-566 (1987)].

Following liver transplantation, moderate to severe neurotoxicity has been shown to occur in 10-20% of patients treated with FK506 and 3-12% of patients treated with cyclosporin. Neurotoxicity has also been associated with serum lipid abnormalities and liver dysfunction.

Other side effects of cyclosporin and/or FK506 include hepatotoxicity, glucose intolerance, hypertension, hirsutism, gastrointestinal symptoms, venous thrombosis, pancreatitis, and gingival hyperplasia [Morris, *J.Heart Lung Transplant*, 12:S275-S286 (1993); Fung *et al.*, *Transpl. Proc.*, 23:3105-3108 (1991); Mason, *Pharmacol. Rev.*, 42:423-434 (1989); Kahan, *N.Engl.J.Med.*, 321:1725-1738 (1989); Thomason *et al.*, *Renal Failure*, 16:731-745 (1994)]. Therefore, in view of the widespread utilization of cyclosporin and FK506 and the inherent side effects of their use, development of alternative immunosuppressives could be extremely beneficial.

For example, it is possible that delocalization of calcineurin from a putative T cell anchoring protein might inhibit calcineurin activity in T cell activation, and thereby providing a T cell-specific immunosuppressive having the utility of cyclosporin or FK506, but fewer side effects. The previous observation that delocalization of PKA from a T cell anchoring protein enhanced IL-2 expression in stimulated cells indicated that anchoring protein-localized PKA in some way contributes to a regulatory role in IL-2 expression during T cell activation. T cell-specific delocalization of PKA may therefore provide a means for enhancing IL-2 secretion *in vivo*, thereby mimicking recombinant IL-2 administration and possibly reducing previously reported toxicity of IL-2 treatment as described below.

IL-2 has been approved for treatment of metastatic renal carcinoma and approximately 15-20% of patients with metastatic renal cell carcinoma or malignant melanoma respond to IL-2 therapy. Some of these

- 42 -

responses are durable, lasting more than 66 months [Dillman, *Cancer Biotherapy*, 9:183-209 (1994); Whittington and Faulds, *Drugs* 46:446-514 (1993)]. While high dose bolus therapy has been associated with several severe side effects (as described below), low dose subcutaneous or continuous
5 infusion therapy produced a modest response rate (12%) while reducing toxicity [Vogelzang *et al.*, *J. Clin. Oncol.*, 11:1809-1816 (1993)].

IL-2 therapy (with and without interferon- α and other agents) has been investigated in the treatment of other malignancies. For example, sustained clinical responses, but no cures, have been obtained in direct
10 application of IL-2 to tumor beds following glioma resection [Merchant *et al.*, *J. Neuro.*, 8:173-188 (1990)]. In still other trials, limited efficacy has been reported in lymphoma [Dillman, *supra*], colorectal carcinoma [Whittington and Faulds, *supra*], limited AML [Bruton and Koeller, *Pharmacotherapy*, 14:635-656 (1994)], ovarian cancer and early bladder cancer [Whittington and
15 Faulds, *supra*]. The number of participants in each of these studies was too small to permit significant conclusions regarding effectiveness, however.

IL-2 has also been used in combination with adoptive immunotherapy, and been demonstrated to be effective for treatment of metastatic renal carcinoma [Pierce *et al.*, *Sem. Oncol.*, 22:74-80 (1995);
20 Belldegrün *et al.*, *J. Urol.*, 150:1384-1390 (1993)]. In addition, IL-2 may also be effective for treatment of certain infectious diseases, by decreasing skin bacterial load and levels of antigen in patients with leprosy following by intradermal injection [Kaplan, *J. Infect. Dis.*, 167(suppl 1):S18-22 (1993)]. Also it has been observed that, as compared to PPD-positive healthy controls,
25 lymphocytes from patients with tuberculosis produce lower levels of IL-2 [Sanchez *et al.*, *Inf. Immun.*, 62:5673-5678 (1994)], suggesting that IL-2 therapy may be of value in treatment of mycobacterial infections.

Despite the potential therapeutic value of IL-2, the cytokine is also associated with significant toxicity [unless otherwise noted, sources are
30 Whittington and Faulds, Dillman and Bruton and Koeller, *supra*]. The major

- 43 -

treatment-limiting side effects is capillary leak syndrome. IL-2 administration increases vascular permeability causing interstitial and pulmonary edema, with patients developing hypotension with a substantial number requiring pressors. Vigorous fluid resuscitation can cause life-threatening pulmonary edema. Up to 20% of patients may require intubation and mechanical ventilation. High bolus administration causes more severe leak than low dose or slow continuous infusions, and in some regimens, 100% of patients require ICU support during IL-2 treatment. Myocarditis, cardiomyopathies and cardiac arrhythmias have also been observed. Acute renal failure may occur as a result of the capillary leak syndrome-induced hypotension.

IL-2 can also cause severe diarrhea with electrolyte imbalances, cholestasis, thyroid abnormalities, and acute pancreatitis. Anemia requiring transfusions occurs in 15-20% of treated patients [MacFarlane *et al.*, *Cancer* 75:1030-1037 (1995)]. Thrombocytopenia with hemorrhage can occur and coagulation pathway defects are common. Over 70% of patients experience changes in mental status, including paranoid delusions, hallucinations, loss of interest, sleep disturbances, and drowsiness. Coma, visual defects, transient ischemic attacks, and paresthesias have also been reported. These drawbacks associated with exogenous IL-2 suggest that alternatives, wherein, for example, endogenous IL-2 production can be modulated and thus eliminate the requirement for exogenous IL-2 treatment, should be explored as potential therapeutics.

In addition to providing possible means to identify immunosuppressive drugs and modulators of IL-2 production, identification of anchoring proteins makes regulation of other cellular activity possible in view of the diverse metabolic pathways in which anchoring proteins have been shown to participate. For example, AKAP 79 is important in regulation of glutamate receptor-regulated ion channels in the post-synaptic density of neurons, presumably via binding PKA, PKC, and calcineurin. PKA regulates activity of AMPA receptor-regulated channels, and delocalization or inhibition

- 44 -

of PKA attenuates AMPA ion channel activity. PKC regulates activity of NMDA receptor-regulated channels, and calcineurin has been shown to desensitize the NMDA receptor to stimuli. These observations indicate that localized kinases (PKA and PKC) may regulate activity of glutamate receptors
5 in neurons. Dephosphorylation by calcineurin is the counter-regulatory mechanism of the NMDA receptors. This model agrees physiologically with evidence of seizures induced by cyclosporin or FK506.

In addition, glutamate receptors have been implicated in many neurological diseases. Glutamate and other excitatory amino acids can
10 produce excitotoxicity in neurons, and excessive stimulation of postsynaptic glutamate receptors has been shown to be toxic to the neurons, causing acute neuronal degeneration. Hypoxia (such as following stroke or cardiac arrest) and CNS trauma have been shown to cause a marked outpouring of glutamate into the extracellular space, which then interacts with glutamate receptors and
15 triggers the excitotoxic cascade. Anti-excitatory agents have been shown to protect against brain injury in animals models [Olney, *Neurobiology of Aging*, 15:259-260 (1994)]. Interestingly, NMDA antagonists are toxic to some types of neurons indicating that glutamate may inhibit other excitatory pathways in those cells. Macrolide antibodies, such as FK506, have also been shown to
20 protect against NMDA, but not kainate, excitotoxicity in cultured neurons [Manev, *et al.*, *Brain Res.*, 624:331-335 (1993)].

Glutamate has also been implicated in Parkinson's Disease. NMDA antagonists protect dopaminergic neurons in substantia nigra in monkeys exposed to MPTP, a chemical that induces Parkinson's syndrome in
25 humans and other primates. Amantidine and memantine are NMDA antagonists and have been used in Europe to treat Parkinson's disease, however, both have been shown to cause psychosis in some patients. There is also some evidence that glutamatergic neurons may be hyperactive in Parkinson's disease and inhibition could decrease the motor symptom's of the
30 disease [Lange and Riederer, *Life Sciences*, 55:2067-2075 (1994)].

- 45 -

Glutamate also plays a role in seizure disorders, participating in initiation, spread, and maintenance of seizure activity. NMDA and non-NMDA antagonists are potent anticonvulsants [Meldrum, *Neurology*, **44**(suppl 8):S14-S23 (1994)]. AMPA receptors have also been implicated in ALS and
5 a trial of a receptor antagonist is currently in progress.⁴⁹

In view of the total of these observations, it is not surprising that numerous

other immunosuppressants are in clinical trials. The following information regarding such trails was obtained from Haydon and Haynes, *Balliere's*
10 *Clin. Gastroentero.*, **8**:455-464 (1994); Thomason and Starzi, *Immunol. Rev.* **1993**, 71-98 (1993); and Morris *J. Heart Lung Transplant.*, **12**:S275-S286 (1993). For example, azaspirane is an SKB compound that suppresses graft cellular infiltrates and induction of IL-2R, and also abolishes IL-2 and IFN- γ production. Apparently azaspirane induces some type of suppressor cell and
15 there is some evidence of synergistic effects with cyclosporin.

As another example, mycophenolate mofetial is a Syntex compound which inhibits purine synthesis and has a T and B cell-selective antiproliferative effect. It depletes antibodies. Mycophenolate mofetial may also deplete adhesion molecules from cell surfaces. While the drug apparently
20 has low toxicity, it may cause leukopenia, and has been used to treat psoriasis for 20 years.

As another example, mizoribine in a Sumitomo compound which inhibits DNA synthesis. The mechanism of action is identical to mycophenolate.

25 As another example, brequinar is a DuPont-Merck compound which inhibits pyrimidine synthesis by blocking dihydroorotate dehydrogenase. Full reports of clinical trials are awaited. The drug has been reported to act synergistically with cyclosporin, but can cause thrombocytopenia, dermatitis and mucositis.

- 46 -

As still another example, 15-Deoxyspergualin is a Nippon-Kayaku compound which predominantly affects monocyte/macrophage function, including inhibition of oxidative metabolism, lysosomal enzyme synthesis, IL-1 production, and cell surface expression of MHC class II
5 antigens. It is 70-90% effective in refractory kidney rejection, but bone marrow toxicity may occur at higher doses.

As another example, leflunomide is a Hoechst compound which inhibits cytokine action, blocks T cell activation and antibody synthesis. It is not toxic to the kidneys or bone marrow.

10 As another example, rapamycin is a Wyeth-Ayerst compound that is related to FK506. It is a prodrug that must bind an immunophillin to be active and does not inhibit calcineurin or block T cell cytokine production. By an unknown mechanism, rapamycin blocks G1 to S transition.

Numerous modifications and variations in the invention as set
15 forth in the above illustrative examples are expected to occur to those skilled in the art. Consequently only such limitations as appear in the appended claims should be placed on the invention.

Numerous modifications and variations in the invention as set
forth in the above illustrative examples are expected to occur to those skilled
20 in the art. Consequently only such limitations as appear in the appended claims should be placed on the invention.

- 47 -

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: Lockerbie, Robert Owen, et al.
- (ii) TITLE OF INVENTION: Calcineurin Inhibitory Compounds and Anchoring Protein
- (iii) NUMBER OF SEQUENCES: 42
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
 - (B) STREET: 233 South Wacker Drive, 6300 Sears Tower
 - (C) CITY: Chicago
 - (D) STATE: Illinois
 - (E) COUNTRY: United States of America
 - (F) ZIP: 60606
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Floppy disk
 - (B) COMPUTER: IBM PC compatible
 - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 - (D) SOFTWARE: PatentIn Release #1.0, Version #1.25
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER:
 - (B) FILING DATE:
 - (C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: US 08/404,731
 - (B) FILING DATE: 15-MAR-1995
- (viii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: US 08/344,227
 - (B) FILING DATE: 23-NOV-1994
- (ix) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: Williams Jr., Joseph A.
 - (B) REGISTRATION NUMBER: 38,659
 - (C) REFERENCE/DOCKET NUMBER: 27866/32861
- (x) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: 312-474-6300
 - (B) TELEFAX: 312-4740448

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 13 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

Arg	Arg	Lys	Arg	Ser	Gln	Ser	Ser	Lys	Glu	Glu	Lys	Pro
1				5					10			

- 48 -

(2) INFORMATION FOR SEQ ID NO:2:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Arg	Arg	Lys	Arg	Ser	Gln	Ser	Ser	Lys	Glu	Glu	Lys	Pro	Leu	Gln
1				5					10					15

(2) INFORMATION FOR SEQ ID NO:3:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 15 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

Arg	Arg	Lys	Arg	Ser	Gln	Ser	Ser	Lys	Glu	Glu	Lys	Pro	Phe	Lys
1				5					10					15

(2) INFORMATION FOR SEQ ID NO:4:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Asp	Leu	Ile	Glu	Glu	Ala	Ala	Val	Ser	Arg	Ile	Val	Asp	Ala	Val	Ile
1					5				10						15
Glu Glu Val Lys Ala Ala Gly Ala															
20															

(2) INFORMATION FOR SEQ ID NO:5:

- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

Gly	Arg	Arg	Asn	Ala	Ile	His	Asp	Ile
1				5				

- 49 -

(2) INFORMATION FOR SEQ ID NO:6:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 2257 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

- (ix) FEATURE:
 (A) NAME/KEY: CDS
 (B) LOCATION: 1..1461

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

CCG	CCC	CCG	CCC	CCG	CCC	CCA	CCG	CCC	CCT	CTC	GGG	GCC	GAC	CGC	GTC	48
Pro	Pro	Pro	Pro	Pro	Pro	Pro	Pro	Pro	Pro	Leu	Gly	Ala	Asp	Arg	Val	
1				5					10					15		
GTC	AAA	GCT	GTT	CCT	TTT	CCC	CCA	ACT	CAT	CGG	CTG	ACA	TCT	GAA	GAA	96
Val	Lys	Ala	Val	Pro	Phe	Pro	Pro	Thr	His	Arg	Leu	Thr	Ser	Glu	Glu	
			20					25					30			
GTG	TTT	GAT	ATG	GAT	GGG	ATA	CCC	AGG	GTT	GAT	GTT	CTG	AAG	AAC	CAC	144
Val	Phe	Asp	Met	Asp	Gly	Ile	Pro	Arg	Val	Asp	Val	Leu	Lys	Asn	His	
		35					40					45				
TTG	GTA	AAA	GAA	GGG	CGG	GTG	GAT	GAA	GAA	ATT	GCA	CTA	AGA	ATT	ATC	192
Leu	Val	Lys	Glu	Gly	Arg	Val	Asp	Glu	Glu	Ile	Ala	Leu	Arg	Ile	Ile	
	50					55					60					
AAT	GAG	GGT	GCT	GCC	ATA	CTT	CGG	CGG	GAG	AAA	ACC	ATG	ATA	GAA	GTA	240
Asn	Glu	Gly	Ala	Ala	Ile	Leu	Arg	Arg	Glu	Lys	Thr	Met	Ile	Glu	Val	
	65				70					75					80	
GAA	GCT	CCA	ATT	ACA	GTG	TGT	GGT	GAC	ATC	CAT	GGC	CAA	TTT	TTT	GAT	288
Glu	Ala	Pro	Ile	Thr	Val	Cys	Gly	Asp	Ile	His	Gly	Gln	Phe	Phe	Asp	
				85					90					95		
CTG	ATG	AAA	CTT	TTT	GAA	GTA	GGA	GGA	TCA	CCT	GCT	AAT	ACA	CGA	TAC	336
Leu	Met	Lys	Leu	Phe	Glu	Val	Gly	Gly	Ser	Pro	Ala	Asn	Thr	Arg	Tyr	
			100					105					110			
CTT	TTT	CTT	GGT	GAT	TAT	GTG	GAC	AGA	GGT	TAT	TTT	AGT	ATA	GAG	TGT	384
Leu	Phe	Leu	Gly	Asp	Tyr	Val	Asp	Arg	Gly	Tyr	Phe	Ser	Ile	Glu	Cys	
		115					120					125				
GTC	TTA	TAT	TTA	TGG	GTC	TTG	AAG	ATT	CTA	TAC	CCA	AGC	ACA	TTA	TTC	432
Val	Leu	Tyr	Leu	Trp	Val	Leu	Lys	Ile	Leu	Tyr	Pro	Ser	Thr	Leu	Phe	
	130					135					140					
CTT	CTG	AGA	GGC	AAC	CAT	GAA	TGC	AGA	CAC	CTT	ACT	GAA	TAT	TTT	ACC	480
Leu	Leu	Arg	Gly	Asn	His	Glu	Cys	Arg	His	Leu	Thr	Glu	Tyr	Phe	Thr	
					150					155					160	
TTT	AAG	CAG	GAA	TGT	AAA	ATT	AAA	TAT	TCA	GAA	AGA	GTC	TAT	GAA	GCT	528
Phe	Lys	Gln	Glu	Cys	Lys	Ile	Lys	Tyr	Ser	Glu	Arg	Val	Tyr	Glu	Ala	
				165					170					175		
TGT	ATG	GAG	GCT	TTT	GAC	AGC	TTG	CCC	CTT	GCT	GCA	CTT	CTA	AAC	CAA	576
Cys	Met	Glu	Ala	Phe	Asp	Ser	Leu	Pro	Leu	Ala	Ala	Leu	Leu	Asn	Gln	
			180					185					190			

- 50 -

CAA Gln	TTT Phe	CTT Leu 195	TGT Cys	GTT Val	CAT His	GGT Gly	GGA Gly 200	CTT Leu	TCA Ser	CCA Pro	GAA Glu	ATA Ile 205	CAC His	ACA Thr	CTG Leu	624
GAT Asp	GAT Asp 210	ATT Ile	AGG Arg	AGA Arg	TTA Leu	GAT Asp 215	AGA Arg	TTT Phe	AAA Lys	GAG Glu	CCA Pro 220	CCT Pro	GCA Ala	TTT Phe	GGA Gly	672
CCA Pro 225	ATG Met	TGT Cys	GAC Asp	TTG Leu	CTA Leu 230	TGG Trp	TCT Ser	GAT Asp	CCT Pro	TCT Ser 235	GAA Glu	GAC Asp	TTT Phe	GGA Gly	AAT Asn 240	720
GAA Glu	AAA Lys	TCA Ser	CAA Gln	GAA Glu 245	CAT His	TTT Phe	AGT Ser	CAT His	AAT Asn 250	ACA Thr	GTT Val	CGA Arg	GGA Gly	TGT Cys 255	TCT Ser	768
TAT Tyr	TTT Phe	TAT Tyr	AAC Asn 260	TAT Tyr	CCA Pro	GCA Ala	GTG Val	TGT Cys 265	GAA Glu	TTT Phe	TTG Leu	CAA Gln	AAC Asn 270	AAT Asn	AAT Asn	816
TTG Leu	TTA Leu	TCG Ser 275	ATT Ile	ATT Ile	AGA Arg	GCT Ala	CAT His 280	GAA Glu	GCT Ala	CAA Gln	GAT Asp	GCA Ala 285	GGC Gly	TAT Tyr	AGA Arg	864
ATG Met	TAC Tyr 290	AGA Arg	AAA Lys	AGT Ser	CAA Gln	ACT Thr 295	ACA Thr	GGG Gly	TTT Phe	CCT Pro	TCA Ser 300	TTA Leu	ATA Ile	ACA Thr	ATT Ile	912
TTT Phe 305	TCG Ser	GCA Ala	CCT Pro	AAT Asn 310	TAC Tyr	TTA Leu	GAT Asp	GTC Val	TAC Tyr	AAT Asn 315	AAT Asn	AAA Lys	GCT Ala	GCT Ala	GTA Val 320	960
CTA Leu	AAG Lys	TAT Tyr	GAA Glu	AAT Asn 325	AAT Asn	GTG Val	ATG Met	AAC Asn	ATT Ile 330	CGA Arg	CAG Gln	TTT Phe	AAT Asn	TGC Cys 335	TCT Ser	1008
CCA Pro	CAT His	CCT Pro	TAT Tyr 340	TGG Trp	TTG Leu	CCC Pro	AAT Asn	TTT Phe 345	ATG Met	GAT Asp	GTC Val	TTT Phe	ACA Thr 350	TGG Trp	TCC Ser	1056
TTA Leu	CCA Pro	TTT Phe 355	GTT Val	GGA Gly	GAA Glu	AAA Lys	GTG Val 360	ACA Thr	GAA Glu	ATG Met	TTG Leu	GTA Val 365	AAT Asn	GTT Val	CTG Leu	1104
AGT Ser	ATT Ile 370	TGT Cys	TCT Ser	GAT Asp	GAT Asp	GAA Glu 375	CTA Leu	ATG Met	ACA Thr	GAA Glu	GGT Gly 380	GAA Glu	GAC Asp	CAG Gln	TTT Phe	1152
GAT Asp 385	GTA Val	GGT Gly	TCA Ser	GCT Ala	GCA Ala 390	GCC Ala	CGG Arg	AAA Lys	GAA Glu	ATC Ile 395	ATA Ile	AGA Arg	AAC Asn	AAG Lys	ATC Ile 400	1200
CGA Arg	GCA Ala	ATT Ile	GGC Gly	AAG Lys 405	ATG Met	GCA Ala	AGA Arg	GTC Val	TTC Phe 410	TCT Ser	GTT Val	CTC Leu	AGG Arg	GAG Glu 415	GAG Glu	1248
AGT Ser	GAA Glu	AGC Ser	GTG Val 420	CTG Leu	ACA Thr	CTC Leu	AAG Lys	GGC Gly 425	CTG Leu	ACT Thr	CCC Pro	ACA Thr	GGG Gly 430	ATG Met	TTG Leu	1296
CCT Pro	A T Ser	GGA ly 435	GTG Val	TTG Leu	CT Ala	GGA Gly	GGA Gly 440	CGG Arg	CA Gln	ACC Thr	TTG Leu	CAA Gln 445	AGT Ser	GGT Gly	AAT Asn	1344

- 51 -

GAT GTT ATG CAA CTT GCT GTG CCT CAG ATG GAC TGG GGC ACA ACT CAC	1392
Asp Val Met Gln Leu Ala Val Pro Gln Met Asp Trp Gly Thr Thr His	
450 455 460	
TCT TTT GCT AAC AAT ACA CAT AAT GCA TGC AGG GAA CTC CTT CTG CTT	1440
Ser Phe Ala Asn Asn Thr His Asn Ala Cys Arg Glu Leu Leu Leu Leu	
465 470 475 480	
TTT AGT TCC TGT CTT AGC AGC TGACATATGC AGGGTATTAT GTGATAGGCA	1491
Phe Ser Ser Cys Leu Ser Ser	
485	
TCTGATTAGT ACCTGGCCAG GGCATAATAT TGATAGAACA AGTTGTCTTT TAACTGAAAA	1551
TAACAATCAG TTTCCCAGAT TTTCATAAGG TGATATGGGG AGCAGCTCAT GTCATAATTC	1611
CGAAATATTT ATTCATTTGT TTAATGCACC CCTTTCTTTC AAAAGCCTCA GTCAAGAATG	1671
TGAATCAGGG ATATATCTAT ATATCTATTT ACACACATAC ATAAATATAT ATAACTAAAA	1731
TGGAAATGTA ATTCGGAGTT TCTTACTTTT AAAATTTACG TAATTGTATT AGATTTTGCT	1791
TATGTTTTCA AGTATTTATT TTTTGAGTTA AAATTCTGCT TAGGCCCCAA AACTTCCTTT	1851
ATGCACTCAT TTGCCAAAAG ATTTATGCTA AATTTTGTAC CCTGGTAAAT GATTAGAGTT	1911
TGTTTTCTGT GGTGTTTGTC AAACGTTCTA TGTATAATTG ACTGTCTGTA ACATGCTGTT	1971
TCCTTCCTCT GCAGATATAG CTGCTTTCCT AAATCTGTCT GTCTTTCTTT AGGATAGCTG	2031
TATGTCTGTA AATATATGTT CAATTAAATT ACTCTATCAG ACGCTTGTCT GTCTTTTGAT	2091
GTAGAAGCAA CTTTGTAGCA CCTTGATTTT AGGTTTGCTG CATTGTGTTGC TGCAC TTGGT	2151
TCAGTCTGAA TATGAATGTA ACATTAGATA TTGAGCTATT GTTATAAAGG GTTGAATTTA	2211
AATCATGTAA GTCAAAATTG AAAGGGTGTT ATAAAGTGTG CCTTTA	2257

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 487 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

Pro	Pro	Pro	Pro	Pro	Pro	Pro	Pro	Pro	Pro	Leu	Gly	Ala	Asp	Arg	Val
1				5						10				15	
Val	Lys	Ala	Val	Pro	Phe	Pro	Pro	Thr	His	Arg	Leu	Thr	Ser	Glu	Glu
			20					25					30		
Val	Phe	Asp	Met	Asp	Gly	Ile	Pro	Arg	Val	Asp	Val	Leu	Lys	Asn	His
		35					40					45			
Leu	Val	Lys	Glu	Gly	Arg	Val	Asp	Glu	Glu	Ile	Ala	Leu	Arg	Ile	Ile
	50					55					60				

- 52 -

Asn Glu ly Ala Ala Ile Leu Arg Arg Glu Lys Thr Met Ile Glu Val
 65 70 75 80
 Glu Ala Pro Ile Thr Val Cys Gly Asp Ile His Gly Gln Phe Phe Asp
 85 90 95
 Leu Met Lys Leu Phe Glu Val Gly Gly Ser Pro Ala Asn Thr Arg Tyr
 100 105 110
 Leu Phe Leu Gly Asp Tyr Val Asp Arg Gly Tyr Phe Ser Ile Glu Cys
 115 120 125
 Val Leu Tyr Leu Trp Val Leu Lys Ile Leu Tyr Pro Ser Thr Leu Phe
 130 135 140
 Leu Leu Arg Gly Asn His Glu Cys Arg His Leu Thr Glu Tyr Phe Thr
 145 150 155 160
 Phe Lys Gln Glu Cys Lys Ile Lys Tyr Ser Glu Arg Val Tyr Glu Ala
 165 170 175
 Cys Met Glu Ala Phe Asp Ser Leu Pro Leu Ala Ala Leu Leu Asn Gln
 180 185 190
 Gln Phe Leu Cys Val His Gly Gly Leu Ser Pro Glu Ile His Thr Leu
 195 200 205
 Asp Asp Ile Arg Arg Leu Asp Arg Phe Lys Glu Pro Pro Ala Phe Gly
 210 215 220
 Pro Met Cys Asp Leu Leu Trp Ser Asp Pro Ser Glu Asp Phe Gly Asn
 225 230 235 240
 Glu Lys Ser Gln Glu His Phe Ser His Asn Thr Val Arg Gly Cys Ser
 245 250 255
 Tyr Phe Tyr Asn Tyr Pro Ala Val Cys Glu Phe Leu Gln Asn Asn Asn
 260 265 270
 Leu Leu Ser Ile Ile Arg Ala His Glu Ala Gln Asp Ala Gly Tyr Arg
 275 280 285
 Met Tyr Arg Lys Ser Gln Thr Thr Gly Phe Pro Ser Leu Ile Thr Ile
 290 295 300
 Phe Ser Ala Pro Asn Tyr Leu Asp Val Tyr Asn Asn Lys Ala Ala Val
 305 310 315 320
 Leu Lys Tyr Glu Asn Asn Val Met Asn Ile Arg Gln Phe Asn Cys Ser
 325 330 335
 Pro His Pro Tyr Trp Leu Pro Asn Phe Met Asp Val Phe Thr Trp Ser
 340 345 350
 Leu Pro Phe Val Gly Glu Lys Val Thr Glu Met Leu Val Asn Val Leu
 355 360 365
 Ser Ile Cys Ser Asp Asp Glu Leu Met Thr Glu Gly Glu Asp Gln Phe
 370 375 380
 Asp Val Gly Ser Ala Ala Ala Arg Lys Glu Ile Ile Arg Asn Lys Ile
 385 390 395 400

- 53 -

Arg Ala Ile Gly Lys Met Ala Arg Val Phe Ser Val Leu Arg Glu Glu
 405 410 415

Ser Glu Ser Val Leu Thr Leu Lys Gly Leu Thr Pro Thr Gly Met Leu
 420 425 430

Pro Ser Gly Val Leu Ala Gly Gly Arg Gln Thr Leu Gln Ser Gly Asn
 435 440 445

Asp Val Met Gln Leu Ala Val Pro Gln Met Asp Trp Gly Thr Thr His
 450 455 460

Ser Phe Ala Asn Asn Thr His Asn Ala Cys Arg Glu Leu Leu Leu Leu
 465 470 475 480

Phe Ser Ser Cys Leu Ser Ser
 485

(2) INFORMATION FOR SEQ ID NO:8:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 28 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

Ser Ile Lys Arg Leu Val Thr Arg Arg Lys Arg Ser Glu Ser Ser Lys
 1 5 10 15

Gln Gln Lys Pro Phe Lys Ala Lys Leu Gln Ser Glu
 20 25

(2) INFORMATION FOR SEQ ID NO:9:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 24 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

Asp Leu Ile Glu Glu Ala Ala Ser Arg Ile Val Asp Ala Val Ile Glu
 1 5 10 15

Gln Val Lys Ala Ala Gly Ala Tyr
 20

(2) INFORMATION FOR SEQ ID NO:10:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 26 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

- 54 -

- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:
GTATTAGCAG GAGATCTTCC TACTTC 26
- (2) INFORMATION FOR SEQ ID NO:11:
- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:
GTGTGTGTAG ATCTGGTGAA AGTCC 25
- (2) INFORMATION FOR SEQ ID NO:12:
- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:
ATTGTAGAGA TCTAAGTAAT TAGGTGCCG 29
- (2) INFORMATION FOR SEQ ID NO:13:
- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:
GCCAATTGCT CAGATCTTGT TTCTTATG 28
- (2) INFORMATION FOR SEQ ID NO:14:
- (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 29 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:
GGAATTCGGA TCCTCGAGA ATCTCGCCG 29

- 55 -

(2) INFORMATION FOR SEQ ID NO:15:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 30 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

CCACTTTGAG ATCTCTACCG TCCTCCAGCC

30

(2) INFORMATION FOR SEQ ID NO:16:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 25 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

CCCTGAGATC TTCAGCTGCT AAGAC

25

(2) INFORMATION FOR SEQ ID NO:17:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 30 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

GGCTGAGATC TGGCAGACCT TGCAAAGTGG

30

(2) INFORMATION FOR SEQ ID NO:18:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 32 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

GTGATGAAGA TCTTACAGTT TAATTGCTCT CC

32

(2) INFORMATION FOR SEQ ID NO:19:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 26 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- 56 -

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

TTCTCCAGAT CTTGGTAAGG ACCATG

26

(2) INFORMATION FOR SEQ ID NO:20:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 30 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

CACCTTCTGT AGATCTTTCA TCATCAGAAC

30

(2) INFORMATION FOR SEQ ID NO:21:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 24 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

CATCGGCAGA TCTCTGAAGA AGTG

24

(2) INFORMATION FOR SEQ ID NO:22:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 29 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

CCATGGCCAA TTTTAGATCT CGATGAAAC

29

(2) INFORMATION FOR SEQ ID NO:23:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 30 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

GGACCATGAG ATCTAATCCA TAAATTGGG

30

- 57 -

(2) INFORMATION FOR SEQ ID NO:24:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 31 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

AAATGGGAGA TCTAATAAGG ATGTGGAGAG C

31

(2) INFORMATION FOR SEQ ID NO:25:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 32 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

GGAGAGCAAT TAAAGATCTA AATGTTTCATC AC

32

(2) INFORMATION FOR SEQ ID NO:26:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 27 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

TTTTCATAGA TCTATACAAG CAGCTTT

27

(2) INFORMATION FOR SEQ ID NO:27:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 36 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

CAACCAGATC TAATGTGGAG AGCAATTAAA CTGTTCG

36

(2) INFORMATION FOR SEQ ID NO:28:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 33 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- 58 -

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

CCAATAAGAG ATCTAAGAGC AATTAACTG TCG

33

(2) INFORMATION FOR SEQ ID NO:29:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 35 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

TGTGAGATCT AATTAACTG TCGAATGTTC ATCAC

38

(2) INFORMATION FOR SEQ ID NO:30:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 32 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

GGAGAGCAGA TCTACTGTCG AATGTTTCATC AC

32

(2) INFORMATION FOR SEQ ID NO:31:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 40 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:

AAGGATAGAT CTAGCAATTA AACTGTCGAA TGTTTCATCAC

40

(2) INFORMATION FOR SEQ ID NO:32:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 54 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:

TACAACTAGT ACCATGGTCG ATGGTCGACA GATCTCTCGA GAAGCTTAGC TAGC

54

- 59 -

(2) INFORMATION FOR SEQ ID NO:33:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 981 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:

```

CAGAGTATCG ATGAAATCTA CAAATATGAC AAAAAACAAC AACAAGAAAT CCTGGCGGCG      60
AAACCCTGGA CTAAGGATCA CCACTACTTT AAATACTGCA AAATCTCAGC ATTGGCTCTA      120
CTGAAAATGG TGATGCATGC CAGGTCAGGA GGCAACTTGG AAGTGATGGG TTTGATGCTC      180
GGGAAAGTCG ACGGCGAGAC CATGATCATC ATGGACAGTT TCGCTTTGAC TGTAGAGGGC      240
ACAGAACTC GAGTAAATGC TCAAGCTGCT GCGTATGAGT ATATGGCTGC ATACATAGAA      300
AATGCCAAAC AGGTTGGCCG CCTTGAGAAT GCAATCGGTT GGTATCATAG CCACCCTGGT      360
TATGGCTGCT GGCTCTCCGG GATTGATGTT AGTACACAGA TGCTGAACCA GCAGTTTCAA      420
GAACCATTTG TAGCAGTGGT GATTGATCCA ACCAGAACAA TCTCTGCAGG AAAAGTGAAT      480
CTTGGCGCCT TTAGGACATA TCCAAAGGGC TACAAACCTC CTGATGAAGG ACCTTCTGAG      540
TACCAGACTA TCCCACCTTA ATAAATAGA AGATTTGGGC GTGCACTGAA ACAATATTAT      600
GCCTTAGAAG TCTCATATTT CAAATCATCT TGGATCGTAA ACTACTTGAG CTTTGGTGGA      660
ATAAATACTG GGTGAATACC CTGAGTCCTC TAGCTTGCTT ACTAATGCAG ACTACACCAC      720
AGGCCAGGTG TTGATTTGTC TGAGAAGTTA GAGCAGTCGG AAGCCCAACT GGGACGTGGC      780
AGTTTCATGT TGGGCTTAGA AACACATGAC CGCAAGTCGG AAGACAACT TGCCAAAGCT      840
ACTAGAGACA GCTGTAAAC CACCATAGAA GCCACCATGG ACTGATGTCT CAGGTTATTA      900
AGGATAAACT GTTAAATCAG ATTAACGTTG TTAGTTACCA CCACGTA CTCAAAGTGG      960
TGTGTGGAAG GAAAAGAGCT C                                     981

```

(2) INFORMATION FOR SEQ ID NO:34:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 919 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:

```

AAACCCTGGA CTAAGGATCA CCACTACTTT AAATACTGCA AAATCTCAGC ATTGGCTCTA      60
CTGAAAATGG TGATGCATGC CAGGTCAGGA GGCAACTTGG AAGTGATGGG TTTGAT CTC      120
GGGAAAGTCG ACGGGGAGAC CATGATCATC ATGGACAGTT TCGCTTTGCT GTAGAGGGCA      180

```

- 60 -

CAGAACTCG AGTAAATGCT CAAGCTGCTG CGTATGAGTA TATGGCTGCA TACATAGAAA	240
ATGCCAAACA GGTGGCCGC CTTGAGAATG CAATCGGTTG GTATCATAGC CACCCTGGTT	300
ATGGCTGCTG GCTCTCCGGG ATTGATGTTA GTACACAGAT GCTGAACCAG CAGTTTCAAG	360
AACCATTTGT AGCAGTGGTG ATTGATCCAA CCAGAACAAT CTCTGCAGGA AAAGTGAATC	420
TTGGCGCCTT TAGGACATAT CCAAAGGGCT ACAAACCTCC GATGAAGGAC CTTCTGAGTA	480
CCAGACTATC CCACCTTAAT AAAATAGAAG ATTTGGGCGT GCACTGAAAC AATATTATGC	540
CTTAGAAGTC TCATATTTCA AATCATCTTG GATCGTAAAC TACTTGAGCT TTGGTGGAAT	600
AAATACTGGG TGAATACCCT GAGTCCTCTA GCTTGCTTAC TAATGCAGAC TACACCACAG	660
GCCAGGTGTT GATTTGTCTG AGAAGTTAGA GCAGTCGGAA GCCCAACTGG GACGTGGCAG	720
TTTCATGTTG GGCTTAGAAA CACATGACCG CAAGTCGGAA GACAAACTTG CCAAAGCTAC	780
TAGAGACAGC TGTA AACCA CCATAGAAGC CACCATGGAC TGATGTCTCA GGTATTAAAG	840
GATAAACTGT TTAATCAGAT TAACGTTGTT AGTTACCACC ACGTACTTCT CAAAGTGGTG	900
TGTGGAAGGA AAAGAGCTC	919

(2) INFORMATION FOR SEQ ID NO:35:

- (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 541 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:35:

GACCACCGAG ATGCCAATTC CAGTGTCTG AGATTTCTGC GAGACCTCAT CCACACAGGA	60
GTAGCCAATG ATTTATCTGT TTTCTTACAG CATGAAGAAG ATTTTGTGTC GGAAGGAACT	120
AATTGGACAG GTGATGAGCC AGCTTGGGCA GCAACTTGTC AGCCAGCTGC TCCACACATG	180
CTGCTTTTGG TTCCCCCTA CACCCTACCC GACGTGGTTG AAGTGCTCTG GGAGATCATG	240
CAGGTTGACA GACCGACTTT CTGTCGGTGG CTAGAGAATT CCTTGAAAGG TTTGCCAAAA	300
GAGACCACAG TGGGAGCTGT CACAGTGACA CATAACAAC TTACAGATTT CCACAAGCAA	360
GTCAC TAGTG CCGAGGAATG TAAGCAAGTT TGCTGGGCCT TGAGAGACTT CACCAGGTTG	420
TTTCGATAGC TCAAGCTCAC ACTCCTGCAC TGTGCCTGTC ATCCAGGAAT GTCTTTTTTT	480
ATTAGAAGAC AGGAAGAAAA CAACCCAGAC TGTGTCCCAC AATCAGAAAC CTCTGTTGTG	540
G	541

- 61 -

(2) INFORMATION FOR SEQ ID NO:36:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 519 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:36:

```

CGAGATGCCA ATTCCAGTGT CATGAGATTT CTGCGAGACC TCATCCACAC AGGAGTAGCC      60
AATGATCATG AAGAAGATTT TGAATTGCGG AAGGAACTAA TTGGACAGGT GATGAGCCAG      120
CTTGGCCAGC AACTTGTCAG CCAGCTGCTC CACACATGCT GCTTTTGTCT TCCCCCTACA      180
CCCTACCCGA CGTGGTTGAA GTGCTCTGGG AGATCATGCA GGTTGACAGA CCGACTTTCT      240
GTCGGTGGCT AGAGAATTCC TTGAAAGGTT TGCCAAAAGA GACCACAGTG GGAGCTGTCA      300
CAGTGACACA TAAACAACCT ACAGATTTCC ACAAGCAAGT CACTAGTGCC GAGGAATGTA      360
AGCAAGTTTG CTGGGCCTTG AGAGACTTCA CCAGGTTGTT TCGATAGCTC AAGCTCACAC      420
TCCTGCACTG TGCCTGTCAT CCAGGAATGT CTTTTTTTAT TAGAAGACAG GAAGAAAACA      480
ACCCAGACTG TGTCCCACAA TCAGAAACCT CTGTTGTGG      519

```

(2) INFORMATION FOR SEQ ID NO:37:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:37:

```

Phe Xaa Arg Arg Lys Lys Ala Ala Lys Ala Leu Ala Pro Lys
 1           5           10

```

(2) INFORMATION FOR SEQ ID NO:38:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:38:

```

Phe Ala Ala Arg Lys Lys Ala Ala Lys Ala Leu Ala Pro Lys
 1           5           10

```

- 62 -

(2) INFORMATION FOR SEQ ID NO:39:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 14 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:39:

Phe Lys Arg Ala Ala Ala Ala Lys Ala Leu Ala Pro Lys
1 5 10

(2) INFORMATION FOR SEQ ID NO:40:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 14 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:40:

Phe Ala Ala Ala Ala Ala Ala Lys Ala Leu Ala Pro Lys
1 5 10

(2) INFORMATION FOR SEQ ID NO:41:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 14 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:41:

Phe Lys Arg Arg Lys Lys Ala Ala Ala Leu Ala Pro Ala
1 5 10

(2) INFORMATION FOR SEQ ID NO:42:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 14 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:42:

Phe Ala Ala Ala Ala Ala Ala Ala Leu Ala Pro Ala
1 5 10

- 63 -

WHAT IS CLAIMED IS:

1. A purified and isolated polynucleotide encoding a pACT 59 polypeptide having the sequence set out in SEQ ID NO: 33.
2. A pACT 59 polypeptide encoded by the polynucleotide of claim 1.
3. A purified and isolated polynucleotide encoding a pACT 74 polypeptide having the sequence set out in SEQ ID NO: 34.
4. A pACT 74 polypeptide encoded by the polynucleotide of claim 3.
5. A purified and isolated polynucleotide encoding a pACT 36 polypeptide having the sequence set out in SEQ ID NO: 35.
6. A pACT 36 polypeptide encoded by the polynucleotide of claim 5.
7. A purified and isolated polynucleotide encoding a pACT 60 polypeptide having the sequence set out in SEQ ID NO: 36.
8. A pACT 36 polypeptide encoded by the polynucleotide of claim 7.
9. A method for identifying a putative inhibitor compound that inhibits binding between an anchoring protein and a binding partner, comprising:

- 64 -

incubating the anchoring protein and a labeled binding partner in the presence and absence of the putative inhibitor compound under conditions suitable for binding between the anchoring protein and the binding partner, wherein the anchoring protein is immobilized on a solid support;

washing unbound binding partner from the solid support;

determining the amount of binding partner bound to the immobilized anchoring protein;

comparing the amount of binding partner bound to the anchoring protein in the presence of the compound to the amount of binding partner that binds the anchoring protein in the absence of the compound; and

determining therefrom whether the compound inhibits binding between the anchoring protein and the binding partner.

10. The method of claim 9, wherein the binding partner is radiolabeled.

11. The method of claim 9, wherein the binding partner is labeled with a fluorophore.

12. The method of claim 9, wherein the binding partner is a type I regulatory subunit of PKA.

13. The method of claim 9, wherein the binding partner is a type II regulatory subunit of PKA.

14. The method of claim 9, wherein the anchoring protein is AKAP 79.

15. The method of claim 9, wherein the binding partner is a calcineurin polypeptide.

- 65 -

16. The method of claim 15 wherein the calcineurin polypeptide is a deletion mutant selected from the group of the calcineurin polypeptides consisting of amino acids 1-487, 1-400, 1-312, 1-204, 1-104, 332-487, 441-487, 332-441, 1-375, 1-354, 30-375, 98-375, 1-347, 1-340, 1-330, 1-320, 1-338, 1-336, 1-334, 1-332, and 1-335 of SEQ ID NO:7.

17. A calcineurin deletion mutant selected from the group of the calcineurin polypeptides consisting of amino acids 1-487, 1-400, 1-312, 1-204, 1-104, 332-487, 441-487, 332-441, 1-375, 1-354, 30-375, 98-375, 1-347, 1-340, 1-330, 1-320, 1-338, 1-336, 1-334, 1-332, and 1-335 of SEQ ID NO:7.

18. A method for enhancing interleukin 2 expression by a T lymphocyte comprising contacting the T lymphocyte with one of the following amino acid sequences:

Gly-Arg-Arg-Asn-Ala-Ile-His-Asp-Ile

or

Asp-Leu-Ile-Glu-Glu-Ala-Ala-Ser-Arg-Ile-Val-Asp-Ala-Val-Ile-Glu-
Gln-Val-Lys-Ala-Ala-Gly-Ala.

19. A method as in claim 18, wherein the amino acid sequence is:

Gly-Arg-Arg-Asn-Ala-Ile-His-Asp-Ile.

20. A method as in claim 19, wherein the amino acid sequence is myristilated.

- 66 -

21. A method as in claim 18, wherein the amino acid sequence is:

Asp-Leu-Ile-Glu-Glu-Ala-Ala-Ser-Arg-Ile-Val-Asp-Ala-Val-Ile-Glu-
Gln-Val-Lys-Ala-Ala-Gly-Ala.

22. A method as in claim 21, wherein the amino acid sequence is myristilated.

23. A method as in claim 18, further comprising activating the T cell with phorbol 12-myristate 13-acetate and ionomycin.

24. A method for isolating calcineurin from a cellular fraction containing the same comprising contacting the cellular fraction with AKAP 79 or a calcineurin-binding fragment thereof immobilized to a solid substrate and eluting calcineurin therefrom.

25. A method for inhibiting calcineurin activity in a cell, comprising contacting the cell with a calcineurin binding peptide comprising the following amino acid sequence:

Arg-Arg-Lys-Arg-Ser-Gln-Ser-Ser-Lys-Glu-Glu-Lys-Pro.

26. A method as in claim 25, wherein the peptide is Arg-Arg-Lys-Arg-Ser-Gln-Ser-Ser-Lys-Glu-Glu-Lys-Pro-Leu-Gln.

27. A method as in claim 25, wherein the peptide is Arg-Arg-Lys-Arg-Ser-Gln-Ser-Ser-Lys-Glu-Glu-Lys-Pro-Phe-Lys.

28. A method as in claim 25, wherein the peptide does not bind PKA.

- 67 -

29. A method for determining if a cell contains a calcineurin-binding and PKA-binding anchoring protein, comprising:

- lysing the cell to form a lysate;
- incubating the lysate with a solid support, which solid support has calcineurin molecules immobilized thereon;
- washing the lysate from the solid support;
- contacting the solid support with a labeled PKA regulatory subunit that binds an anchoring protein;
- washing the regulatory subunit from the solid support;
- detecting label remaining on the solid support;
- determining therefrom the presence of a calcineurin-binding and PKA-binding anchoring protein in the cell.

1/5




a*b**c*

FIG. 1

2/5




FIG. 2


3/5

Mu clone 11.1	-----	PPPPPPPPPP	GCADRUVKAV	PPPPPTTRLTS	EEVFD	OGIP	40	
Hu Calcineurin A1	MAAPEPARAA	PPPPPPPPPP	GCADRUVKAV	PPPPPTTRLTS	EEVFD	OGIP	50	
Mu clone 11.1		RVDVLKNELV	KEGRVDEEIA	LRIINEGAAY	LRREKTHIEV	EAPITVCGDI	90	
Hu Calcineurin A1		RVDVLKNELV	KEGRVDEEIA	LRIINEGAAY	LRREKTHIEV	EAPITVCGDI	100	
Mu clone 11.1		EGQFFDLNKL	FEVGGSPANT	RYLFLGDYVD	RGYFSIEVL	-----	130	
Hu Calcineurin A1		EGQFFDLNKL	FEVGGSPANT	RYLFLGDYVD	RGYFSIEVL	GTEDISTINPM	150	
Mu clone 11.1	-----	YL WVLKILYPTST	LFLLRGNHEC	RHLTEYPTTK	QECKIKYSER		172	
Hu Calcineurin A1	NNINECVL	YL WVLKILYPTST	LFLLRGNHEC	RHLTEYPTTK	QECKIKYSER		200	
Mu clone 11.1		VYEACHEAND	SIFLAALING	QFLCVBGGLS	PEINTLODIR	RLDRFKEPPA	222	
Hu Calcineurin A1		VYEACHEAND	SIFLAALING	QFLCVBGGLS	PEINTLODIR	RLDRFKEPPA	250	
Mu clone 11.1		FGPMCDLLWS	DPSDFGNEK	SOERFSENTV	RCCSYFYNYF	AVCEFLQNNN	272	
Hu Calcineurin A1		FGPMCDLLWS	DPSDFGNEK	SOERFSENTV	RCCSYFYNYF	AVCEFLQNNN	300	
Mu clone 11.1		LLSIIRAHEA	QDAGYRMYRK	SQTIGFPSLI	TIFSAPNYLD	VYNNKAAVLK	322	
Hu Calcineurin A1		LLSIIRAHEA	QDAGYRMYRK	SQTIGFPSLI	TIFSAPNYLD	VYNNKAAVLK	350	
Mu clone 11.1		YENNVMMIRQ	FNCSPRPYWL	PNFMVVTWS	LRFVGEKYTE	MLVNVLSICS	372	
Hu Calcineurin A1		YENNVMMIRQ	FNCSPRPYWL	PNFMVVTWS	LRFVGEKYTE	MLVNVLSICS	400	
Mu clone 11.1		DDELMTEGED	QFD	GSAAAR	KEIIRNKIRA	IGKQARVTSV	LREESESVLT	422
Hu Calcineurin A1		DDELMTEGED	QFD	GSAAAR	KEIIRNKIRA	IGKQARVTSV	LREESESVLT	449
Mu clone 11.1		LKGLTPTQML	PSGVLACGRQ	TLQSGNDVMQ	LAVPQMDWGT	PHSFANNERN	472	
Hu Calcineurin A1		LKGLTPTQML	PSGVLACGRQ	TLQSGNDVMQ	LAVPQMDWGT	PHSFANNERN	499	
Mu clone 11.1		ACREELLIFS	SCLSS				487	
Hu Calcineurin A1		ACREELLIFS	SCLSS				514	


FIG. 3

4/5

Fig. 4

**FORSKOLIN/IBMX INDUCED cAMP
PRODUCTION IN JURKAT T-CELLS**

5/5



PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/12, 15/54, 15/55, C07K 14/47, C12N 9/12, 9/10, C07K 1/113, 7/06, C12Q 1/42, 1/48, G01N 33/68	A3	(11) International Publication Number: WO 96/16172 (43) International Publication Date: 30 May 1996 (30.05.96)
(21) International Application Number: PCT/US95/16039 (22) International Filing Date: 22 November 1995 (22.11.95) (30) Priority Data: 08/344,227 23 November 1994 (23.11.94) US 08/404,731 15 March 1995 (15.03.95) US 08/503,226 17 July 1995 (17.07.95) US (71) Applicants: ICOS CORPORATION [US/US]; 22021 20th Avenue, S.E., Bothell, WA 98021 (US). THE STATE OF OREGON, acting by and through THE OREGON STATE BOARD OF HIGHER EDUCATION, and on behalf of OREGON HEALTH SCIENCES UNIVERSITY [US/US]; 3181 S.W. Sam Jackson Park Road, Portland, OR 97201-3098 (US). (72) Inventors: LOCKERBIE, Robert, Owen; 11111 109th Place, N.E., Kirkland, WA 98033 (US). COGHLAN, Vincent, M.; 2930 S.W. Periander, Portland, OR 97201 (US). HOWARD, Monique, L.; 4723 48th Avenue S.E., Seattle, WA 98118 (US). GALLATIN, William, M.; 8412 S.E. 33rd Place, Mercer Island, WA 98040 (US). SCOTT, John, D.; 6630 S.W. Gable Parkway, Portland, OR 97255 (US).		(74) Agent: WILLIAMS, Joseph, A., Jr.; Marshall, O'Toole, Gerstein, Murray & Borun, 6300 Sears Tower, 233 South Wacker Drive, Chicago, IL 60606-6402 (US). (81) Designated States: AU, BR, CA, CN, CZ, FI, HU, JP, MX, NO, PL, RU, SK, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> (88) Date of publication of the international search report: 29 August 1996 (29.08.96)
(54) Title: MODULATORS OF ANCHORING PROTEIN FUNCTION (57) Abstract The present invention provides compositions and methods useful for isolating calcineurin as well as inhibiting calcineurin activity. The compositions are peptides that contain regions that are homologous to calcineurin-binding regions of AKAP 79. Also provided are methods for determining if a cell contains a calcineurin-binding and PKA-binding anchoring protein that are useful for identifying additional proteins that bind both calcineurin and PKA. Another aspect of the present invention is methods for enhancing expression of interleukin 2 by T cells.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 95/16039

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 6 C12N15/12 C12N15/54 C12N15/55 C07K14/47 C12N9/12
 C12N9/10 C07K1/113 C07K7/06 C12Q1/42 C12Q1/48
 G01N33/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07K C12N C12Q G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 267, no. 24, 25 August 1992, MD US, pages 16816-16823, XP002005105 CARR, D. ET AL.: "Localization of the cAMP-dependent protein kinase to the postsynaptic densities by A-Kinase Anchoring Proteins" cited in the application see the whole document ---	9,10,13, 14,18, 19,25-28
A	WO,A,93 03364 (HARVARD COLLEGE ;UNIV LELAND STANFORD JUNIOR (US)) 18 February 1993 see page 5, line 27 - line 34 see page 9, line 27 - line 34 see page 11, line 1 - line 18 see page 20, line 15 - page 22, line 28 --- -/-	9,10,13, 15,18,24

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *A* document member of the same patent family

Date of the actual completion of the international search

10 June 1996

Date of mailing of the international search report

10.07.96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
 Fax (+ 31-70) 340-3016

Authorized officer

Andres, S

INTERNATIONAL SEARCH REPORT

International Application No

PCI/US 95/16039

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 267, no. 19, 5 July 1992, MD US, pages 13376-13382, XP002005106 CARR, D. ET AL.: "Association of the type II cAMP-dependent protein kinase with a human thyroid RII-anchoring protein" cited in the application see the whole document ---	9,10,13, 18,21
A	NATURE, vol. 368, 28 April 1994, LONDON GB, pages 853-856, XP002005107 ROSEN MUND, C. ET AL.: "Anchoring of protein kinase A is required for modulation of AMPA/kainate receptors on hippocampal neurons" cited in the application see the whole document ---	18,19,21
A	NATURE, vol. 357, 25 June 1992, LONDON GB, pages 695-697, XP002005108 CLIPSTONE, N. & CRABTREE, G.: "Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation" cited in the application see the whole document ---	18,23
	BIOCHEMISTRY, vol. 31, no. 16, 28 April 1992, pages 3896-3901, XP000310587 LIU J ET AL: "INHIBITION OF T CELL SIGNALING BY IMMUNOPHILIN-LIGAND COMPLEXES CORRELATES WITH LOSS OF CALCINEURIN PHOSPHATASE ACTIVITY" see the whole document ---	18
F	JOURNAL OF EXPERIMENTAL MEDICINE, (1993 NOV 1) 178 (5) 1813-7, XP000572884 PALIOGIANNI, F. ET AL.: "Prostaglandin E2 and other cyclic AMP elevating agents inhibit interleukin 2 gene transcription by counteracting calcineurin -dependent pathways." see the whole document ---	18
P,X	SCIENCE, (1995 JAN 6) 267 (5194) 108-11, XP002005109 COGHLAN, V. ET AL.: "Association of protein kinase A and protein phosphatase 2B with a common anchoring protein." see the whole document ---	25-29
	---	-/--

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 95/16039

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
T	<p>BIOCHEMICAL SOCIETY TRANSACTIONS, (1995 AUG) 23 (3) 592-6, XP000572269 COGHLAN, V. ET AL.: "Subcellular targeting of kinases and phosphatases by association with bifunctional anchoring proteins." see the whole document -----</p>	1-29

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 18-23, 25-28
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 18-23 and 25-28 as far as it concerns an "in vivo" method, are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
Claim 8 is inconsistent in its wording as pACT36 is coded by the polynucleotide of claim 5 and not of claim 7. For the purpose of the search, the ISA has interpreted claim 8 as referring to pACT60 which is indeed encoded by SEQ ID 36.
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

information on patent family members

i/US 95/16039

Form PCT/ISA 210 (parent family annex) (July 1992)

